Cover
Cover - USD ($) | 12 Months Ended | ||
Dec. 31, 2020 | Feb. 26, 2021 | Jun. 30, 2020 | |
Cover [Abstract] | |||
Document Type | 10-K | ||
Amendment Flag | false | ||
Document Fiscal Year Focus | 2020 | ||
Document Fiscal Period Focus | FY | ||
Entity Central Index Key | 0001637761 | ||
Current Fiscal Year End Date | --12-31 | ||
Entity Public Float | $ 225,436,595 | ||
Document Period End Date | Dec. 31, 2020 | ||
Entity File Number | 001-36905 | ||
Entity Registrant Name | SeaSpine Holdings Corporation | ||
Entity Incorporation, State or Country Code | DE | ||
Entity Tax Identification Number | 47-3251758 | ||
Entity Address, Address Line One | 5770 Armada Drive | ||
Entity Address, City or Town | Carlsbad | ||
Entity Address, State or Province | CA | ||
Entity Address, Postal Zip Code | 92008 | ||
Entity Address, Country | US | ||
City Area Code | 760 | ||
Local Phone Number | 727-8399 | ||
Title of 12(b) Security | Common Stock | ||
Trading Symbol | SPNE | ||
Security Exchange Name | NASDAQ | ||
Entity Well-known Seasoned Issuer | No | ||
Entity Voluntary Filers | No | ||
Entity Current Reporting Status | Yes | ||
Entity Interactive Data Current | Yes | ||
Entity Filer Category | Accelerated Filer | ||
Entity Small Business | true | ||
Entity Emerging Growth Company | false | ||
Entity Shell Company | false | ||
Entity Common Stock, Shares Outstanding | 27,932,790 | ||
Document Transition Report | false | ||
Document Annual Report | true | ||
ICFR Auditor Attestation Flag | true |
CONSOLIDATED STATEMENTS OF OPER
CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) shares in Thousands, $ in Thousands | 12 Months Ended | |
Dec. 31, 2020 | Dec. 31, 2019 | |
Income Statement [Abstract] | ||
Revenues | $ 154,345 | $ 159,083 |
Cost of Goods and Services Sold | 56,841 | 57,979 |
Gross profit | 97,504 | 101,104 |
Operating expenses: | ||
Selling and Marketing Expense | 84,304 | 83,445 |
General and Administrative Expense | 35,874 | 33,594 |
Research and development | 16,258 | 15,125 |
Intangible amortization | 3,169 | 3,169 |
Impairment of Intangible Assets, Finite-lived | 1,325 | 4,993 |
Total operating expenses | 140,930 | 140,326 |
Operating loss | (43,426) | (39,222) |
Other income, net | (463) | (302) |
Loss before income taxes | (42,963) | (38,920) |
Provision for income taxes | 218 | 356 |
Net loss | $ (43,181) | $ (39,276) |
Net Loss per share, basic and diluted (in dollars per share) | $ (1.59) | $ (2.07) |
Weighted average shares used to compute basic and diluted net loss per share | 27,222 | 18,977 |
CONSOLIDATED STATEMENTS OF COMP
CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS - USD ($) $ in Thousands | 12 Months Ended | |
Dec. 31, 2020 | Dec. 31, 2019 | |
Statement of Comprehensive Income [Abstract] | ||
Net loss | $ (43,181) | $ (39,276) |
Other comprehensive (loss) income | ||
Foreign currency translation adjustments | 690 | (171) |
Other Comprehensive Income (Loss), Securities, Available-for-Sale, Unrealized Holding Gain (Loss) Arising During Period, after Tax | 0 | 3 |
Comprehensive loss | $ (42,491) | $ (39,444) |
CONSOLIDATED BALANCE SHEETS
CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands | Dec. 31, 2020 | Dec. 31, 2019 |
Current assets: | ||
Cash and cash equivalents | $ 76,813 | $ 20,199 |
Accounts Receivable, after Allowance for Credit Loss, Current | 26,154 | 24,902 |
Inventories, net | 54,041 | 47,155 |
Prepaid expenses and other current assets | 3,884 | 3,906 |
Total current assets | 160,892 | 96,162 |
Property, plant and equipment, net | 31,422 | 25,751 |
Operating Lease, Right-of-Use Asset | 7,658 | 0 |
Intangible assets, net | 13,883 | 19,173 |
Other assets | 546 | 632 |
Total assets | 214,401 | 141,718 |
Current liabilities: | ||
Accounts payable, trade | 5,006 | 7,448 |
Accrued compensation | 8,198 | 7,879 |
Accrued commissions | 8,199 | 7,843 |
Short-term Debt | 1,114 | 0 |
Contingent consideration liabilities | 49 | 1,864 |
Operating Lease, Liability, Current | 2,147 | 0 |
Other accrued expenses and current liabilities | 6,014 | 5,444 |
Total current liabilities | 30,727 | 30,478 |
Long-term Debt, Excluding Current Maturities | 5,059 | 0 |
Operating Lease, Liability, Noncurrent | 6,802 | 0 |
Other liabilities | 95 | 1,480 |
Total liabilities | 42,683 | 31,958 |
Commitments and contingencies | ||
Stockholders' equity: | ||
Preferred stock, $0.01 par value; 15,000 authorized; no shares issued and outstanding at December 31, 2020 and December 31, 2019 | 0 | 0 |
Common stock, $0.01 par value; 60,000 authorized; 27,729 and 19,124 shares issued and outstanding at December 31, 2020 and 2019, respectively | 277 | 191 |
Additional paid-in capital | 388,574 | 284,211 |
Accumulated other comprehensive income | 2,124 | 1,434 |
Accumulated deficit | (219,257) | (176,076) |
Total stockholders' equity | 171,718 | 109,760 |
Total liabilities and stockholders' equity | $ 214,401 | $ 141,718 |
CONSOLIDATED BALANCE SHEETS (Pa
CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($) $ in Thousands | Dec. 31, 2020 | Dec. 31, 2019 |
Statement of Financial Position [Abstract] | ||
Allowance for doubtful accounts receivable | $ 192 | $ 111 |
Preferred stock par value (in dollars per share) | $ 0.01 | $ 0.01 |
Preferred stock authorized (in shares) | 15,000,000 | 15,000,000 |
Preferred stock issued (in shares) | 0 | 0 |
Preferred stock outstanding (in shares) | 0 | 0 |
Common stock par value (in dollars per share) | $ 0.01 | $ 0.01 |
Common stock authorized (in shares) | 60,000,000 | 60,000,000 |
Common stock issued (in shares) | 27,729,000 | 19,124,000 |
Common stock outstanding (in shares) | 27,729,000 | 19,124,000 |
CONSOLIDATED STATEMENTS OF CASH
CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands | 12 Months Ended | |
Dec. 31, 2020 | Dec. 31, 2019 | |
OPERATING ACTIVITIES: | ||
Net loss | $ (43,181) | $ (39,276) |
Adjustments to reconcile net loss to net cash used in operating activities: | ||
Depreciation and amortization | 10,725 | 10,347 |
Instrument replacement expense | 2,799 | 2,281 |
Other Asset Impairment Charges | 210 | 30 |
Impairment of Intangible Assets, Finite-lived | 1,325 | 4,993 |
Provision for excess and obsolete inventories | 5,515 | 3,623 |
Stock-based compensation | 10,357 | 7,806 |
Loss/(gain) from change in fair value of contingent consideration liabilities | 176 | (263) |
Other Operating Activities, Cash Flow Statement | 96 | 361 |
Changes in assets and liabilities: | ||
Accounts receivable | (1,119) | (4,621) |
Inventories | (10,480) | (5,924) |
Prepaid expenses and other current assets | 40 | (420) |
Other non-current assets | (93) | (50) |
Accounts payable | (2,691) | (1,458) |
Accrued commissions | 342 | 2,385 |
Other accrued expenses and current liabilities | 1,396 | (1) |
Other non-current liabilities | (16) | (90) |
Net cash used in operating activities | (24,599) | (20,277) |
INVESTING ACTIVITIES: | ||
Payments to Acquire Property, Plant, and Equipment | (16,085) | (12,834) |
Payments to Acquire Intangible Assets | (950) | 0 |
Payments to Acquire Debt Securities, Available-for-sale | (25,007) | 0 |
Maturities of short-term investments | 25,000 | 30,000 |
Net cash (used in) provided by investing activities | (17,042) | 17,166 |
FINANCING ACTIVITIES: | ||
Proceeds from Short-term Debt | 7,173 | 0 |
Repayments of Short-term Debt | 1,000 | 0 |
Proceeds from issuance of common stock- employee stock purchase plan and exercise of stock options | 2,632 | 1,440 |
Proceeds from issuance of common stock, net of offering costs | 91,622 | 0 |
Repurchases of common stock for income tax withheld upon vesting of restricted stock awards and restricted stock units | (2,164) | (2,129) |
Payment of contingent royalty consideration liabilities in connection with acquisition of business | (125) | (140) |
Net cash provided by (used in) financing activities | 98,138 | (829) |
Effect of exchange rate changes on cash and cash equivalents | 117 | (94) |
Net change in cash and cash equivalents | 56,614 | (4,034) |
Cash and cash equivalents at beginning of period | 20,199 | 24,233 |
Cash and cash equivalents at end of period | 76,813 | 20,199 |
Supplemental cash flow information: | ||
Interest Paid, Excluding Capitalized Interest, Operating Activities | 176 | 155 |
Income Taxes Paid | 148 | 101 |
Non-cash investing and financing activities[Abstract] | ||
Capital Expenditures Incurred but Not yet Paid | 1,209 | 713 |
Fair Value of Assets Acquired | 150 | 850 |
Stock Issued | $ 2,000 | $ 0 |
CONSOLIDATED STATEMENTS OF STOC
CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($) $ in Thousands | Total | Common Stock | Additional Paid-In Capital | Accumulated Other Comprehensive Income (Loss) | Accumulated Deficit |
Balance at beginning of period (in shares) at Dec. 31, 2018 | 18,669,000 | ||||
Balance at beginning of period at Dec. 31, 2018 | $ 142,085 | $ 187 | $ 277,096 | $ 1,602 | $ (136,800) |
Increase (Decrease) in Stockholders' Equity [Roll Forward] | |||||
Net loss | (39,276) | (39,276) | |||
Foreign currency translation adjustment | (171) | (171) | |||
Other Comprehensive Income (Loss), Securities, Available-for-Sale, Unrealized Holding Gain (Loss) Arising During Period, after Tax | 3 | 3 | |||
Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures | 319,000 | ||||
Restricted stock issued | 2 | $ 3 | (1) | ||
Stock Issued During Period, Shares, Employee Stock Purchase Plans | 120,000 | ||||
Issuance of common stock under employee stock purchase plan | 1,210 | $ 1 | 1,209 | ||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period | 17,000 | ||||
Issuance of common stock- exercise of stock options | 230 | 230 | |||
Treasury Stock, Shares, Acquired | (1,000) | ||||
Treasury Stock, Value, Acquired, Cost Method | (2,129) | 2,129 | |||
Adjustments to Additional Paid in Capital, Share-based Compensation, Stock Options, Requisite Service Period Recognition | $ 7,806 | 7,806 | |||
Balance at end of period (in shares) at Dec. 31, 2019 | 19,124,000 | 19,124,000 | |||
Balance at end of period at Dec. 31, 2019 | $ 109,760 | $ 191 | 284,211 | 1,434 | (176,076) |
Increase (Decrease) in Stockholders' Equity [Roll Forward] | |||||
Net loss | (43,181) | (43,181) | |||
Foreign currency translation adjustment | 690 | 690 | |||
Other Comprehensive Income (Loss), Securities, Available-for-Sale, Unrealized Holding Gain (Loss) Arising During Period, after Tax | 0 | ||||
Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures | 340,000 | ||||
Restricted stock issued | 2 | $ 3 | (1) | ||
Stock Issued During Period, Shares, New Issues | 7,820,000 | ||||
Stock Issued During Period, Value, New Issues | 91,622 | $ 78 | 91,544 | ||
Stock Issued During Period, Shares, Employee Stock Purchase Plans | 153,000 | ||||
Issuance of common stock under employee stock purchase plan | 1,366 | $ 2 | 1,364 | ||
Stock Issued During Period, Shares, Acquisitions | 176,000 | ||||
Stock Issued During Period, Value, Acquisitions | 2,000 | $ 2 | 1,998 | ||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period | 117,000 | ||||
Issuance of common stock- exercise of stock options | 1,266 | $ 1 | 1,265 | ||
Treasury Stock, Shares, Acquired | (1,000) | ||||
Treasury Stock, Value, Acquired, Cost Method | (2,164) | 2,164 | |||
Adjustments to Additional Paid in Capital, Share-based Compensation, Stock Options, Requisite Service Period Recognition | $ 10,357 | 10,357 | |||
Balance at end of period (in shares) at Dec. 31, 2020 | 27,729,000 | 27,729,000 | |||
Balance at end of period at Dec. 31, 2020 | $ 171,718 | $ 277 | $ 388,574 | $ 2,124 | $ (219,257) |
BUSINESS
BUSINESS | 12 Months Ended |
Dec. 31, 2020 | |
Text Block [Abstract] | |
Business Description and Basis of Presentation | BUSINESS AND BASIS OF PRESENTATION Business SeaSpine Holdings Corporation was incorporated in Delaware on February 12, 2015 in connection with the spin-off of the orthobiologics and spinal implant business of Integra LifeSciences Holdings Corporation, a diversified medical technology company. The spin-off occurred on July 1, 2015. Unless the context indicates otherwise, (i) references to "SeaSpine" or the "Company" refer to SeaSpine Holdings Corporation and its wholly-owned subsidiaries, and (ii) references to "Integra" refer to Integra LifeSciences Holdings Corporation and its subsidiaries other than SeaSpine. SeaSpine is a global medical technology company focused on the design, development and commercialization of surgical solutions for the treatment of patients suffering from spinal disorders. SeaSpine has a comprehensive portfolio of orthobiologics and spinal implant solutions to meet the varying combinations of products that neurosurgeons and orthopedic spine surgeons need to perform fusion procedures in the lumbar, thoracic and cervical spine. The Company believes this broad combined portfolio of orthobiologics and spinal implant products is essential to meet the “complete solution” requirements of such surgeons. Basis of Presentation and Principles of Consolidation The Company’s financial statements are presented on a consolidated basis. The Company prepared the consolidated financial statements included in this report in accordance with accounting principles generally accepted in the U.S. (GAAP). The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. Intercompany accounts and transactions have been eliminated in consolidation. Under current SEC rules, generally, a company qualifies as a "smaller reporting company" if it has a public float of less than $250 million as of the last business day of its most recently completed second fiscal quarter. If a company qualifies as a smaller reporting company on that date, it may elect to reflect that determination and use the smaller reporting company scaled disclosure accommodations in its subsequent SEC filings until the beginning of the first quarter of the fiscal year following the date it determines it does not qualify as a smaller reporting company. The Company's public float as of June 30, 2020, the last business day of its most recent second fiscal quarter, was less than $250 million, and as such, the Company qualifies as a smaller reporting company, elected to reflect that determination and intends to use certain of the scaled disclosure accommodations in its SEC filings made during and for the year ended December 31, 2021. Concentration of Risk Integra and PcoMed, LLC (PcoMed) entered into a supply agreement in May 2013 (the Supply Agreement), which was subsequently assigned to the Company by Integra in May 2015. For the year ending December 31, 2020, the sales of products incorporating the NanoMetalene® technology provided under the Supply Agreement exceeded 10% of the Company's revenue. Pursuant to the Supply Agreement, PcoMed granted the Company a worldwide exclusive right for PcoMed to treat certain of the Company’s products with PcoMed’s proprietary technology (Treatment) for use in the spinal interbody and intervertebral market (Treated Products). PcoMed serves as the sole supplier of the Treatment. As consideration for exclusivity and the Treatment, the Company paid to PcoMed initial milestone payments prior to the initial sale of any Treated Products and the Company pays PcoMed a low single digit royalty on the Company’s net sales of all Treated Products. In the event the Company fails to meet any of its payment obligations, the exclusive right will, at PcoMed’s option and following a cure period, convert to a non-exclusive right. The Supply Agreement contains customary representations and termination provisions, including for material breach and bankruptcy. Each of the Company and PcoMed retain the rights to their respective intellectual property. The Supply Agreement expired on January 15, 2021 and on March 1, 2021, the Company entered into a new supply agreement with PcoMed, which terminates in January 2024. The Company's financial instruments that are exposed to concentrations of credit risk consist primarily of cash. Cash balances are maintained primarily at major financial institutions in the United States and exceed the regulatory limit of $250,000 insured by the Federal Deposit Insurance Corporation (FDIC). The Company has not experienced any credit losses associated with its cash balances. |
SUMMARY OF SIGNIFICANT ACCOUNTI
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES | 12 Months Ended |
Dec. 31, 2020 | |
Accounting Policies [Abstract] | |
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES | SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Use of Estimates Preparing consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent liabilities, and the reported amounts of revenues and expenses. Significant estimates affecting amounts reported or disclosed in the consolidated financial statements include allowances for doubtful accounts receivable and sales returns and other credits, net realizable value of inventories, discount rates and estimated projected cash flows used to value and test impairments of identifiable intangible and long-lived assets, assumptions related to the timing and probability of product launch dates, discount rates matched to the estimated timing of payments, probability of success rates and discount adjustments on the related cash flows for contingent considerations in business combinations, depreciation and amortization periods for identifiable intangible and long-lived assets, computation of taxes, valuation allowances recorded against deferred tax assets, the valuation of stock-based compensation and loss contingencies. These estimates are based on historical experience and on various other assumptions believed to be reasonable under the current circumstances. Actual results could differ from these estimates. The full extent to which the COVID-19 pandemic will directly or indirectly impact the Company's business, results of operations and financial condition, including revenues, expenses, manufacturing, research and development costs and employee-related compensation, will depend on future developments that are highly uncertain, including as a result of new information that may emerge concerning COVID-19 and the actions taken to contain it or treat COVID-19, as well as the economic impact on local, regional, national and international customers and markets. The Company has made estimates of the impact of the pandemic within its financial statements and there may be changes to those estimates in future periods. Actual results may differ from these estimates. Cash and Cash Equivalents The Company considers all highly liquid investments with a maturity of 90 days or less at the date of purchase to be cash equivalents. Cash and cash equivalents include cash readily available in checking and money market accounts. Fair Value of Financial Instruments The carrying amounts of cash, cash equivalents, receivables, accounts payable and accrued expenses at December 31, 2020 and 2019, are considered to approximate fair value because of the short-term nature of those items. The Company measures certain assets and liabilities in accordance with authoritative guidance which requires fair value measurements to be classified and disclosed in one of the following three categories: Level 1: Quoted prices (unadjusted) in active markets that are accessible at the measurement date for assets or liabilities. Level 2: Observable prices that are based on inputs not quoted on active markets, but corroborated by market data. Level 3: Unobservable inputs are used when little or no market data is available. The carrying amounts of contingent consideration liabilities at December 31, 2020 and 2019 related to business combinations are measured at fair value on a recurring basis, and are classified within Level 3 of the fair value hierarchy because they use significant unobservable inputs. See Note 5, "Fair Value Measurements" , below, for further information. Trade Accounts Receivable and Allowances Trade accounts receivable in the accompanying consolidated balance sheets are presented net of allowances for doubtful accounts and sales returns and other credits. The Company grants credit to customers in the normal course of business, but generally does not require collateral or any other security to support its receivables. The Company evaluates the collectability of accounts receivable based on a combination of factors. In circumstances where a specific customer is unable to meet its financial obligations to the Company, a provision to the allowances for doubtful accounts is recorded to reduce the net recognized receivable to the amount that is reasonably expected to be collected. For all other customers, a provision to the allowances for doubtful accounts is recorded based on factors including the length of time the receivables are past due, the current business environment and the Company’s historical experience. Provisions to the allowances for doubtful accounts are recorded to general and administrative expenses. Account balances are charged off against the allowance when it is probable that the receivable will not be recovered. Inventories Inventories, consisting of purchased materials, direct labor and manufacturing overhead, are stated at the lower of cost, the value determined by the first-in, first-out method, or net realizable value. At each balance sheet date, the Company evaluates inventories for excess quantities, obsolescence or shelf life expiration. This evaluation includes analysis of the Company's current and future strategic plans, historical sales levels by product, projections of future demand, the risk of technological or competitive obsolescence for products, general market conditions, a review of the shelf life expiration dates for products, as well as the feasibility of reworking or using excess or obsolete products or components in the production or assembly of other products that are not obsolete or for which there are not excess quantities in inventory. To the extent that management determines there are excess or obsolete inventory or quantities with a shelf life that is too near its expiration for the Company to reasonably expect that it can sell those products prior to their expiration, the Company adjusts the carrying value to estimated net realizable value. The Company capitalizes inventory costs associated with certain products prior to regulatory approval, based on management’s judgment of probable economic benefit. The Company could be required to expense previously capitalized costs related to pre-approval inventory upon a change in such judgment, due to, among other potential factors, a denial or delay of approval by necessary regulatory bodies or a decision by management to discontinue the related development program. No material amounts were capitalized at December 31, 2020 or 2019. Property, Plant, and Equipment Property, plant and equipment are stated at historical cost less accumulated depreciation and any impairment charges. The Company provides for depreciation using the straight-line method over the estimated useful lives of the assets. Leasehold improvements are amortized over the lesser of the lease term or the useful life. The cost of major additions and improvements is capitalized, while maintenance and repair costs that do not improve or extend the lives of the respective assets are charged to operations as incurred. The cost of computer software obtained for internal use is accounted for in accordance with the Codification 350-40, Internal-Use Software. The cost of purchased spinal instruments that the Company consigns to hospitals and independent sales agents to support surgeries is initially capitalized as construction in progress. The amount is then either reclassified to spinal instruments and sets and depreciation is initiated when instruments are put together in a newly built set with spinal implants, or directly expensed for the instruments used to replace damaged instruments in an existing set. The depreciation expense and direct expense for replacement instruments are recorded in selling and marketing expense. Leases The Company determines if an arrangement is a lease at inception. The Company's leases primarily relate to administrative, manufacturing, research, and distribution facilities and various manufacturing, office and transportation equipment. Lease assets represent the Company's right to use an underlying asset for the lease term and lease liabilities represent the obligation to make lease payments arising from the lease. Lease assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. As the Company's leases do not provide an implicit rate, the Company's incremental borrowing rate is used as a discount rate, based on the information available at the commencement date, in determining the present value of lease payments. Lease assets also include the impact of any prepayments made and are reduced by impact of any lease incentives. The Company made an accounting policy election for short-term leases, such that the Company will not recognize a lease liability or lease asset on its balance sheet for leases with a lease term of twelve months or less as of the commencement date. Rather, any short-term lease payments will be recognized as an expense on a straight-line basis over the lease term. The current period short-term lease expense reasonably reflects the Company's short-term lease commitments. The Company made a policy election for all classifications of leases to combine lease and non-lease components and to account for them as a single lease component. Variable lease payments are excluded from the lease liability and recognized in the period in which the obligation is incurred. Additionally, lease terms may include options to extend or terminate the lease when it is reasonably certain the Company will exercise the option. Business Combinations The purchase price of each acquisition is allocated to the net assets acquired based on estimates of their fair values at the date of the acquisition. Any purchase price in excess of these net assets is recorded as goodwill, and any fair value of these net assets, excluding goodwill, in excess of the purchase price is recorded as a bargain purchase gain. The allocation of purchase price in certain cases may be subject to revision based on the final determination of fair values during the measurement period, which may be up to one year from the acquisition date. Contingent consideration liability is recognized at the estimated fair value on the acquisition date. Subsequent changes to the fair value of contingent consideration liability are recognized in the statement of operations. Contingent consideration liability related to acquisitions consist of commercial milestone payments and contingent royalty payments, and are valued using discounted cash flow techniques. The fair value of commercial milestone payments and contingent royalty payments reflects management’s expectations of probability and amount of payment, and increases or decreases as the probability and amount of payment or expectation of timing of payment changes. Identifiable Intangible Assets Identifiable intangible assets are initially recorded at fair value at the time of acquisition, generally using an income or cost approach. The Company capitalizes costs incurred to renew or extend the term of recognized intangible assets and amortizes those costs over their expected useful lives. Impairment of Long-Lived Assets Long-lived assets held and used by the Company, including property, plant and equipment and intangible assets, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. For purposes of evaluating the recoverability of long-lived assets to be held and used, a recoverability test is performed using projected undiscounted net cash flows applicable to the long-lived assets. If an impairment exists, the amount of such impairment is calculated based on the estimated fair value of the asset. Impairments to long-lived assets to be disposed of are recorded based upon the difference between the carrying value and the fair value of the applicable assets. The Company determined an impairment exists for certain intangible assets during the year ended December 31, 2020 and 2019. Excluding the impairment of spinal instruments, there was no impairment of tangible long-lived assets in any of the periods presented. See Note 4, "Balance Sheet Details" , below, for additional information. Foreign Currency The Company generates revenues outside the United States in multiple foreign currencies including euros, Swiss francs and in U.S. dollar-denominated transactions conducted with customers who generate revenue in currencies other than the U.S. dollar. The Company also incurs operating expenses in euros and Swiss francs. All assets and liabilities of foreign subsidiaries which have a functional currency other than the U.S. dollar are translated at the rate of exchange at year-end, while elements of the income statement are translated at the average exchange rates in effect during the year. The net effect of these translation adjustments is shown as a component of accumulated other comprehensive income. These currency translation adjustments are not currently adjusted for income taxes as they relate to permanent investments in non-U.S. subsidiaries. Foreign currency transaction gains and losses are reported in other income (expense), net. Income Taxes The Company recognizes tax benefits in its financial statements when its uncertain tax positions are more likely than not to be sustained upon audit. The amount recognized is measured as the largest amount of benefit that is greater than 50 percent likely of being realized upon ultimate settlement. The Company recognizes deferred tax assets for deductible temporary differences, operating loss carryforwards and tax credit carryforwards. Deferred tax assets are reduced by valuation allowance if it is more likely than not that some portion, or all, of the deferred tax assets will not be realized. Revenue Recognition Net sales are derived primarily from the sale of orthobiologics and spinal implant products globally. Revenue is recognized when obligations under the terms of a contract with the Company's customer are satisfied which occurs with the transfer of control of the Company's products. This occurs either upon shipment or delivery of goods, depending on whether the contract is Free on Board (FOB) origin or FOB destination, or, in other situations such as consignment arrangements, when the products are used in a surgical procedure (implanted in a patient). Revenue is measured as the amount of consideration the Company expects to receive in exchange for transferring products to a customer (transaction price). To the extent that the transaction price includes variable consideration, such as discounts, list price discounts, rebates, volume discounts and customer payment penalties, the Company estimates the amount of variable consideration that should be included in the transaction price utilizing the most likely amount method. Variable consideration is included in the transaction price if, in the Company’s judgment, it is probable that a significant future reversal of cumulative revenue under the contract will not occur. Estimates of variable consideration and determination of whether to include estimated amounts in the transaction price are based largely on an assessment of the Company’s anticipated performance and all information (historical, current and forecasted) that is reasonably available. The Company reduces revenue by estimates of potential future product returns and other allowances. Provisions for product returns and other allowances are recorded as a reduction to revenue in the period sales are recognized. The Company estimates the amount of sales returns and allowances that will eventually be incurred. Certain contracts with stocking distributors contain provisions requiring the Company to repurchase inventory upon termination of the contract or discontinuation of a product line. Included in the sales returns reserve within other current liabilities is an estimate of repurchases that are likely to be made under these provisions. Management analyzes sales programs that are in effect, contractual arrangements, market acceptance and historical trends when evaluating the adequacy of sales returns and allowance accounts. In certain sales arrangements, the Company fulfills its obligations and bills the customer for the products prior to the shipment of goods. The Company allocates the transaction price to the multiple performance obligations under these contracts, including delivery of the products and the third-party logistics (3PL) performance obligations. Revenue related to product sales under these arrangements is not recognized until the Company delivers the products to the customer’s dedicated space within the Company’s facility, at which point the customer obtains control of the products. Revenue from the related 3PL obligations consists of revenue from storage of products which is recognized ratably over the service period, and revenue from shipping services which is recognized upon performance of such obligation. Product royalties account for less than 1% of total revenue for any of the periods presented, and are estimated and recognized in the same period that the royalty-based products are sold by licensees. The Company estimates and recognizes royalty revenue based upon communication with licensees, historical information and expected sales trends. Differences between actual revenues and estimated royalty revenues are adjusted in the period in which they become known, which is typically the following quarter. Historically, such adjustments have not been material. See Note 10, "Segment and Geographic Information" , below for a presentation of the Company's disaggregated revenue. Shipping and Handling Fees and Costs The Company has elected to account for shipping and handling activities as fulfillment activities. As such, the Company does not evaluate shipping and handling as promised services to its customers. Shipping and handling costs of $2.5 million for shipments of loaned spinal implants and instrumentation sets and costs incurred for internal movement of inventory were recorded in selling and marketing expense during each of the years ended December 31, 2020 and 2019, respectively. Research and Development Research and development costs, including salaries, stock-based compensation, depreciation, consultant, clinical study, product registration and other external fees, and facility costs directly attributable to research and development activities, are expensed in the period in which they are incurred. Stock-Based Compensation The Company's stock-based compensation has been recognized through the consolidated statement of operations and the Company's additional paid-in capital account on the consolidated balance sheet. The Company recognizes the expense related to the fair value of their stock-based compensation awards. Stock-based compensation expense for stock option awards was based on the fair value on the grant date using the Black-Scholes-Merton option pricing model. The fair value of restricted stock granted prior to the spin-off was based on the Integra’s stock price at the grant date, and the fair value of restricted stock granted after the spin-off was based on the Company's stock price at the grant date. The long form method was used in the determination of the windfall tax benefit. The stock-based compensation is initially measured at the fair value of the awards on the grant date and is then recognized on a ratable basis in the financial statements over the requisite service period of the award. Stock-based compensation expense was $10.4 million in 2020 and $7.8 million in 2019. Concentration of Credit Risk Financial instruments, which potentially subject the Company to concentrations of credit risk, consist principally of cash, which is held at major financial institutions, and trade receivables. The Company’s products are sold on an uncollateralized basis and on credit terms based upon a credit risk assessment of each customer. A portion of the Company’s trade receivables to customers outside the United States includes sales to foreign stocking distributors, who then sell to government owned or supported healthcare systems. The ongoing economic conditions in certain European countries, especially Greece, Ireland, Italy, Portugal and Spain remain uncertain. Accounts receivable from customers in these countries are not a material amount of the Company’s overall receivables. None of the Company’s customers accounted for 10% or more of the net sales or accounts receivable for any of the periods presented. Recent Accounting Standards Not Yet Adopted In June 2016, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU or Update) No. 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments , which requires credit losses on most financial assets measured at amortized cost, including trade receivables, and certain other instruments to be measured using an expected credit loss model, referred to as the current expected credit loss (CECL) model. Under this model, entities will estimate credit losses over the entire contractual term of the instrument. The new standard will be effective for the Company beginning January 1, 2023. The FASB subsequently issued other related ASUs that amend ASU No. 2016-13 to provide clarification and additional guidance. The Company is evaluating the impact of this standard on its consolidated financial statements. In August 2018, the FASB issued Update No. 2018-15, Intangibles-Goodwill and Other-Internal Use Software (Subtopic 350-40) . The amendments in this Update align the requirements for capitalizing implementation costs incurred in a hosting arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software (and hosting arrangements that include an internal-use software license). The new standard will be effective for the Company beginning on January 1, 2021. Early adoption is permitted. The adoption of this new standard is not expected to have a material impact on its consolidated financial statements. In April 2019, the FASB issued Update No. 2019-04, Codification Improvements to Topic 326, Financial Instruments-Credit Losses, Topic 815, Derivatives and Hedging, and Topic 825, Financial Instruments . This Update includes several amendments to the FASB Accounting Standards Codification (Codification) intended to clarify, improve, or correct errors therein. Some amendments do not require transition guidance and are effective upon issuance. The amendments requiring transition guidance have the same effective date as Update No. 2016-13 and will be effective for the Company beginning on January 1, 2023. The Company is evaluating the impact of this standard on its consolidated financial statements. Recently Adopted Accounting Standards In February 2016, the FASB issued Update No. 2016-02, Leases (Topic 842). The new standard requires lessees to recognize lease liabilities and corresponding right-of-use assets for all leases with lease terms of greater than twelve months. It also changes the definition of a lease and expands the disclosure requirements of lease arrangements. The new standard must be adopted using the modified retrospective approach. In July 2018, the FASB issued Update No. 2018-10, Codification Improvements to Topic 842 (Leases) and Update No. 2018-11, Leases (Topic 842): Targeted Improvements. In March 2019, the FASB issued Update No. 2019-01, Leases (Topic 842): Codification Improvements. In November 2019, the FASB issued Update No. 2019-10, Financial Instruments - Credit Losses (Topic 326), Derivatives and Hedging (Topic 815), and Leases (Topic 842): Effective Dates, which modifies the effective dates for Topic 842. The amendments in Updates Nos. 2018-10, 2018-11, 2019-01, and 2019-10 provide additional clarification and implementation guidance on certain aspects of Topic 842 and have the same effective date and transition requirements as ASU 2019-10. The Company early adopted the new standard beginning on January 1, 2020. The Company adopted the new standard electing the optional transition method that allows for a cumulative-effect adjustment in the period of adoption and did not restate prior periods. The Company applied the transition package of practical expedients allowed by the standard. As a result of the Company’s adoption of the new standard, the Company recorded right-of-use assets and lease liabilities of $9.1 million and $10.5 million, respectively, for existing operating leases in the consolidated balance sheets at January 1, 2020. Additionally, the Company reversed $1.4 million of deferred rent liabilities previously recorded under the previous accounting guidance. The adoption of this new standard had no material impact on its consolidated results of operations or cash flows. In June 2018, the FASB issued Update No. 2018-07, Compensation-Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting . This Update requires an entity to apply the requirements of Topic 718 to nonemployee awards except for specific guidance on inputs to an option pricing model and the attribution of cost (that is, the period of time over which share-based payment awards vest and the pattern of cost recognition over that period). The amendments specify that Topic 718 applies to all share-based payment transactions in which a grantor acquires goods or services to be used or consumed in a grantor’s own operations by issuing share-based payment awards. The amendments also clarify that Topic 718 does not apply to share-based payments used to effectively provide (1) financing to the issuer or (2) awards granted in conjunction with selling goods or services to customers as part of a contract accounted for under Topic 606. The new standard was effective for the Company beginning on January 1, 2020. The adoption of this new standard had no material impact on its consolidated financial statements. In August 2018, the FASB issued Update No. 2018-13, Fair Value Measurement (Topic 820)-Disclosure Framework-Changes to the Disclosure Requirements for Fair Value Measurement . The amendments in this Update modify the disclosure requirements on fair value measurements in Topic 820 based on the concepts in the Concepts Statement including the consideration of costs and benefits. The new standard was effective for the Company beginning on January 1, 2020. The adoption of this new standard had no material impact on its consolidated financial statements. In March 2020, the FASB issued Update No. 2020-04, Reference Rate Reform (Topic 848), Facilitation of the Effects of Reference Rate Reform on Financial Reporting . The amendments in this Update apply only to contracts, hedging relationships, and other transactions that reference LIBOR, or another reference rate expected to be discontinued, due to the reference rate reform. The new standard was effective for the Company beginning March 12, 2020. The adoption of this new standard had no material impact on its consolidated financial statements. Basic and diluted net loss per share was calculated using the weighted-average number of shares of common stock outstanding |
Debt
Debt | 12 Months Ended |
Dec. 31, 2020 | |
Debt Disclosure [Abstract] | |
Debt Disclosure | Credit Agreement In December 2015, the Company entered into a three one There were no amounts outstanding under the Credit Facility at December 31, 2020 or 2019. At December 31, 2020, the Company had $23.0 million of current borrowing capacity under the Credit Facility before the requirement to maintain the minimum fixed charge coverage ratio as discussed below. Debt issuance costs and legal fees related to the Credit Facility totaling $0.6 million were recorded as a deferred asset and are being amortized ratably over the term of the arrangement. Borrowings under the Credit Facility accrue interest at the rate then applicable to base rate loans (as customarily defined), unless and until converted into LIBOR rate loans (as customarily defined) in accordance with the Credit Facility. Borrowings bear interest at a floating annual rate equal to (a) during any month for which the Company's average excess availability (as customarily defined) is greater than $20.0 million, (i) base rate plus 1.25 percentage points for base rate loans and (ii) LIBOR rate plus 2.25 percentage points for LIBOR rate loans, (b) during any month for which the Company's average excess availability is greater than $10.0 million but less than or equal to $20.0 million, (i) base rate plus 1.50 percentage points for base rate loans and (ii) LIBOR rate plus 2.50 percentage points for LIBOR rate loans and (c) during any month for which the Company's average excess availability is less than or equal to $10.0 million, (i) base rate plus 1.75 percentage points for base rate loans and (ii) LIBOR rate plus 2.75 percentage points for LIBOR rate loans. The Company also pays an unused line fee based on the average amount borrowed under the Credit Facility for the most recently completed month. If such average amount is 25% or greater of the maximum borrowing capacity, the unused fee will be equal to 0.375% per annum of the amount unused under the Credit Facility, and if such average amount is less than 25%, the unused line fee will be equal to 0.50% per annum of the amount unused under the Credit Facility. The unused line fee is due on the first day of each month. The Credit Facility contains various customary affirmative and negative covenants, including prohibiting the Company from incurring indebtedness without the lender’s consent. The Credit Facility also includes a financial covenant, that requires the Company to maintain a minimum fixed charge coverage ratio of 1.10 to 1.00 for the applicable measurement period, if the Company's Total Liquidity (as defined in the Credit Facility) is less than $5.0 million. The Company was in compliance with all applicable covenants at December 31, 2020. The Credit Facility also includes customary events of default, including events of default relating to non-payment of amounts due under the Credit Facility, material inaccuracy of representations and warranties, violation of covenants, bankruptcy and insolvency, failure to comply with health care laws, violation of certain of the Company’s existing agreements, and the occurrence of a change of control. Under the Credit Facility, if an event of default occurs, the lender will have the right to terminate the commitments and accelerate the maturity of any loans outstanding. |
BALANCE SHEET DETAILS
BALANCE SHEET DETAILS | 12 Months Ended |
Dec. 31, 2020 | |
Balance Sheet Related Disclosures [Abstract] | |
BALANCE SHEET DETAILS | BALANCE SHEET DETAILS Inventories, net. Inventories consisted of: December 31, 2020 December 31, 2019 (In thousands) Finished goods $ 37,689 $ 30,042 Work in process 10,087 10,847 Raw materials 6,265 6,266 $ 54,041 $ 47,155 Property, Plant and Equipment . Property, plant and equipment balances and corresponding useful lives were as follows: December 31, 2020 December 31, 2019 Useful Lives (In thousands) Leasehold improvements $ 5,976 $ 5,878 Shorter of lease term or useful life Machinery and production equipment 9,577 8,562 3-10 years Spinal instruments and sets 30,275 25,511 4-5 years Information systems and hardware 7,554 7,442 3-7 years Furniture and fixtures 1,640 1,412 3-5 years Construction in progress 12,645 9,716 Total 67,667 58,521 Less accumulated depreciation and amortization (36,245) (32,770) Property, plant and equipment, net $ 31,422 $ 25,751 The balance of construction in progress as of December 31, 2020 and 2019 consists primarily of spinal instruments not yet placed into service. Depreciation and amortization expenses totaled $6.5 million and $4.9 million for the years ended December 31, 2020 and 2019, respectively, and included $1.0 million and $0.9 million of expenses that were presented within cost of goods sold for the years ended December 31, 2020 and 2019, respectively. The cost of purchased instruments used to replace damaged instruments in existing sets and recorded directly to the instrument replacement expense totaled $2.8 million and $2.3 million for the years ended December 31, 2020 and 2019, respectively. Identifiable Intangible Assets. Primarily as a result of an expected shift in future product revenue mix more toward a parallel expanding interbody device designed based on the Company’s internally developed technology and, in turn, lower future revenue anticipated for the lordotic expanding implant based on technology the Company acquired from N.L.T. Spine Ltd. (NLT) and NLT Spine, Inc., a wholly owned subsidiary of NLT, the Company's estimated future net sales associated with those NLT product technologies decreased. Accordingly, the Company evaluated the ongoing value of the product technology intangible assets associated with the acquisition of these assets. Based on this evaluation, the Company determined that intangible assets with a carrying amount of $1.6 million were no longer recoverable and were impaired, and the Company wrote those intangible assets down to their estimated fair value of $0.3 million at March 31, 2020. During the year ended December 31, 2019, the Company shifted its commercialization strategy with respect to the product technologies it acquired of NLT due to market trend factors, new features necessary to be competitive, and more cost-effective internal development initiatives and the Company's estimated future net sales associated with those product technologies decreased. Accordingly, the Company evaluated the ongoing value of the product technology intangible assets associated with the acquisition of these assets. Based on this evaluation, the Company determined that intangible assets with a carrying amount of $6.8 million were no longer recoverable and were impaired, and the Company wrote those intangible assets down to their estimated fair value of $1.8 million at June 30, 2019. Significant estimates used in determining the estimated fair value include measurements estimating cash flows and determining the appropriate discount rate, which are considered Level 3 inputs under Codification 820. During the year ended December 31, 2020 and 2019, the Company recognized $0.3 million and $0.9 million, respectively, of product technology intangible assets related to the achievement of certain licensed technology development milestones under a license agreement. The components of the Company’s identifiable intangible assets were: December 31, 2020 Weighted Cost Accumulated Net (In thousands) Product technology 12 years $ 32,891 $ (29,766) $ 3,125 Customer relationships 12 years 56,830 (46,072) 10,758 Trademarks/brand names — 300 (300) — $ 90,021 $ (76,138) $ 13,883 December 31, 2019 Weighted Cost Accumulated Net (In thousands) Product technology 12 years $ 34,158 $ (28,912) $ 5,246 Customer relationships 12 years 56,830 (42,903) 13,927 Trademarks/brand names — 300 (300) — $ 91,288 $ (72,115) $ 19,173 |
FAIR VALUE MEASUREMENTS
FAIR VALUE MEASUREMENTS | 12 Months Ended |
Dec. 31, 2020 | |
Fair Value Disclosures [Abstract] | |
FAIR VALUE MEASUREMENTS | FAIR VALUE MEASUREMENTS The fair values of the Company’s assets and liabilities, including contingent consideration liabilities, are measured at fair value on a recurring basis, and are determined under the fair value categories as follows (in thousands): Total Quoted Price in Active Market (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) December 31, 2020: Contingent consideration liabilities- current $ 49 $ — $ — $ 49 Contingent consideration liabilities- non-current 95 — — 95 Total contingent consideration $ 144 $ — $ — $ 144 Total Quoted Price in Active Market (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) December 31, 2019: Contingent consideration liabilities- current $ 1,864 $ — $ — $ 1,864 Contingent consideration liabilities- non-current 230 — — 230 Total contingent consideration $ 2,094 $ — $ — $ 2,094 Under the terms of the 2016 asset purchase agreement between the Company and NLT, the Company is obligated to pay up to a maximum $5.0 million in milestone payments to NLT, payable at the Company's election in cash or in shares of its common stock. Such milestone payments are contingent on the Company's achievement of four independent events related to the commercialization of the product technologies the Company acquired in the transaction. To date, the Company achieved two of the milestones, one each during the three months ended June 30, 2020 and September 30, 2020, and paid the $2.0 million of milestone payments in shares of its common stock in July 2020 and August 2020, respectively. The remaining two milestones will not be achieved. Additionally, the Company must pay royalty payments, in cash, to NLT equal to declining (over time) percentages of the Company’s future net sales of certain of the acquired product technologies not to exceed $43.0 million in the aggregate. The Company has the option to terminate any future obligation to make royalty payments by making a one-time cash payment to NLT of $18.0 million. Contingent consideration liabilities are classified within Level 3 of the fair value hierarchy because they use significant unobservable inputs. For those liabilities, fair value is determined using a probability-weighted discounted cash flow model and significant inputs which are not observable in the market. The significant inputs include assumptions related to the timing and probability of the product launch dates, estimated future sales of the products, estimated commission rates, discount rates matched to the timing of payments, and probability of success rates. The following table sets forth the changes in the estimated fair value of the Company’s liabilities measured on a recurring basis using significant unobservable inputs (Level 3). The loss from change in fair value of contingent milestone and royalty payments resulted from the timing of payments, success rates, the passage of time, updated discount rates matched to the estimated timing of payments, actual net sales of certain products for the year ended December 31, 2020, and estimated net sales for future royalty payment periods. A change in estimated net sales for future royalty payment periods would be expected to have a material impact on the fair value of royalty payments. Year Ended December 31, 2020 2019 (in thousands) Beginning Balance as of January 1 $ 2,094 $ 2,496 Contingent consideration liabilities settled (2,126) (139) Loss/(Gain) from change in fair value of contingent consideration recorded in general and administrative expenses 176 (263) Ending Balance as of December 31 $ 144 $ 2,094 |
STOCK-BASED COMPENSATION
STOCK-BASED COMPENSATION | 12 Months Ended |
Dec. 31, 2020 | |
Share-based Payment Arrangement [Abstract] | |
Shareholders' Equity and Share-based Payments | EQUITY AND STOCK-BASED COMPENSATION Common Stock In July 2020 and August 2020, the Company issued 100,100 shares and 75,585 shares of its common stock to NLT, respectively, as settlement of contingent milestone payments pursuant to the terms of the asset purchase agreement entered into with NLT in August 2016. See Note 5, "Fair Value Measurements" above. In January 2020, the Company entered into an Underwriting Agreement with Piper Sandler & Co. and Canaccord Genuity LLC relating to the issuance and sale of 6,800,000 shares of the Company’s common stock at a price to the public of $12.50 per share, before underwriting discounts and commissions. Under the terms of that agreement, the Company granted the underwriters an option, exercisable for 30 days, to purchase up to an additional 1,020,000 shares of common stock. The underwriters exercised this option and the offering closed on January 10, 2020 with the sale of 7,820,000 shares of common stock, resulting in net proceeds to the Company of approximately $91.6 million, after deducting underwriting discounts and commissions and estimated offering expenses payable by the Company. The offering was made pursuant to the Company’s shelf registration statement on Form S-3 that was declared effective on May 22, 2019. Equity Award Plans Stock-based compensation expense, all related to employees and non-employee directors, was recognized as follows: December 31, 2020 2019 (In Thousands) Selling and marketing $ 2,530 1,628 General and administrative 5,607 $ 4,607 Research and development 1,831 1,278 Cost of goods sold 389 293 Total stock-based compensation expense 10,357 7,806 No estimated tax benefit related to stock-based compensation expense was recognized for the years ended December 31, 2020 and 2019. As of June 30, 2015, Integra had stock options, restricted stock awards, performance stock awards, contract stock awards and restricted stock units outstanding under three plans, the 2000 Equity Incentive Plan, the 2001 Equity Incentive Plan, and the 2003 Equity Incentive Plan. In connection with the spin-off, Integra equity awards granted to individuals who became employees of SeaSpine were converted to equity awards denominated in SeaSpine common stock. In general, each post-conversion award is subject to the same terms and conditions as were applicable to the pre-conversion award. In May 2015, the Company adopted the 2015 Incentive Award Plan, which was subsequently amended and restated with approval of the Company's stockholders. In February and March 2018, the Company's board of directors approved amendments to the plan that increased the share reserve by an aggregate of 2,726,000 shares over the then-existing share reserve thereunder, subject to stockholder approval. The Company's stockholders approved both amendments in May 2018. On April 13, 2020, the Company's board of directors approved an amendment to the plan that, among other things, increased the share reserve by an aggregate of 3,500,000 shares over the then-existing share reserve thereunder, subject to stockholder approval. The Company's stockholders approved the amendment on June 3, 2020 (the 2015 Incentive Award Plan, as amended and restated to date, the Restated Plan). Under the Restated Plan, the Company can grant its employees, non-employee directors and consultants incentive stock options and non-qualified stock options, restricted stock, performance stock, dividend equivalent rights, stock appreciation rights, stock payment awards and other incentive awards. The aggregate number of shares that may be issued or transferred pursuant to awards under the Restated Plan is the sum of (1) the number of shares issuable upon exercise or vesting of the number of Integra equity awards converted to the Company's equity awards under the Restated Plan as of the date of the spin-off and (2) 9,735,500 shares of its common stock in respect of awards granted under the Restated Plan. As of December 31, 2020, 4,011,104 shares were available for issuance under the Restated Plan. In June 2018, the Company established the 2018 Employment Inducement Incentive Award Plan (the 2018 Inducement Plan). The terms of the 2018 Inducement Plan are substantially similar to the terms of the Restated Plan with these principal exceptions: (1) incentive stock options may not be granted under the 2018 Inducement Plan; (2) there are no annual limits on awards that may be issued to an individual under the 2018 Inducement Plan; (3) awards granted under the 2018 Inducement Plan are not required to be subject to any minimum vesting period; and (4) awards may be granted under the 2018 Inducement Plan only to those individuals and in those circumstances described below. An aggregate of 2,000,000 shares are reserved under the 2018 Inducement Plan. As of December 31, 2020, 1,914,793 shares were available for issuance under the 2018 Inducement Plan. As a result of the approval of the amendment to the Restated Plan by the Company's stockholders in June 2020, no awards will be granted under the 2018 Inducement Plan in the future. In August 2020, the Company adopted the 2020 Employment Inducement Incentive Award Plan (the 2020 Inducement Plan). The terms of the 2020 Inducement Plan are substantially similar to the terms of the 2015 Incentive Award Plan with four principal exceptions: (1) incentive stock options may not be granted under the 2020 Inducement Plan; (2) there are no annual limits on awards that may be issued to an individual under the 2020 Inducement Plan; (3) awards granted under the 2020 Inducement Plan are not required to be subject to any minimum vesting period; and (4) awards may be granted under the 2020 Inducement Plan only to those individuals and in those circumstances described below. An aggregate of 2,000,000 shares are reserved under the 2020 Inducement Plan. As of December 31, 2020, 1,928,257 share were available for issuance under the 2020 Inducement Plan. Both the 2018 Inducement Plan and the 2020 Inducement Plan were adopted by the Company’s board of directors without stockholder approval pursuant to Rule 5635(c)(4) of the Nasdaq Listing Rules. In accordance with Rule 5635(c)(4) of the Nasdaq Listing Rules, awards under those plans may only be made to an employee who has not previously been an employee or member of the Company's board of directors or of any board of directors of any parent or subsidiary of the Company, or following a bona fide period of non-employment by the Company or a parent or subsidiary, if he or she is granted such award in connection with his or her commencement of employment with the Company or a subsidiary and such grant is an inducement material to his or her entering into employment with the Company or such subsidiary. Restricted Stock Awards and Restricted Stock Units Restricted stock award and restricted stock unit grants to employees generally have a requisite service period of three years, and restricted stock award and restricted stock unit grants to non-employee directors generally have a requisite service period of one year. Both are subject to graded vesting. The Company expenses the fair value of restricted stock awards and restricted stock units on an accelerated basis over the vesting period or requisite service period, whichever is shorter. Stock-based compensation expense related to all equity awards includes an estimate for forfeitures. The expected forfeiture rate of all equity-based compensation is based on historical experience of pre-vesting forfeitures on awards by each homogeneous group of shareowners. For awards granted to non-executive employees, the forfeiture rate is estimated to be 13% and 14% annually for the years ended December 31, 2020 and 2019, respectively. There is no forfeiture rate applied to awards granted to non-employee directors or executive employees because their pre-vesting forfeitures are anticipated to be highly unlikely. As individual awards become fully vested, stock-based compensation expense is adjusted to recognize actual forfeitures. The following table summarizes restricted stock awards and restricted stock units granted to SeaSpine employees and non-employee directors during 2020: Restricted Stock Awards and Units Shares Weighted Average Grant Date Fair Value Per Share Unvested, January 1, 2020 852 $12.21 Granted 512 12.12 Cancellations (42) 13.64 Released/Vested (525) 11.25 Unvested, December 31, 2020 797 12.71 The weighted average grant date fair value of restricted stock awards and restricted stock units granted during 2020 and 2019 was $12.12 and $16.31, respectively. The total fair value of shares subject to restricted stock awards and restricted stock units that vested in 2020 and 2019 was $6.0 million and $4.3 million, respectively. The Company recognized $5.7 million and $5.9 million in expense related to restricted stock awards and restricted stock units for the years ended December 31, 2020 and 2019, respectively. As of December 31, 2020, there was approximately $2.9 million of unrecognized compensation expense related to the unvested portions of restricted stock awards and restricted stock units. This expense is expected to be recognized over a weighted-average period of approximately 1.2 years. Stock Options Stock option grants to employees generally have a requisite service period of four years, and stock option grants to non-employee directors generally have a requisite service period of one year. Both are subject to graded vesting. The Company records stock-based compensation expense associated with stock options on an accelerated basis over the applicable vesting period within each grant and based on their fair value at the date of grant using the Black-Scholes-Merton option pricing model. The following weighted-average assumptions were used in the calculation of fair value for options granted during the period indicated. December 31, 2020 2019 Expected dividend yield 0 % 0 % Risk-free interest rate 1.3 % 2.5 % Expected volatility 46.4 % 30.2 % Expected term (in years) 4.9 5.0 The Company considered that it has never paid, and does not currently intend to pay, cash dividends. The risk-free interest rates are derived from the U.S. Treasury yield curve in effect on the date of grant for instruments with a remaining term similar to the expected term of the options. The expected volatility is calculated based upon the historical volatility of the Company's share prices. The expected term is calculated using the historical weighted average term of the Company’s options. In addition, the Company applies an expected forfeiture rate when amortizing stock-based compensation expense. The expected forfeiture rate of options is based on historical experience of pre-vesting forfeitures on awards by each homogeneous group of shareowners. For options granted to non-executive employees, the forfeiture rate is estimated to be 13% and 14% annually for the years ended December 31, 2020 and 2019, respectively. There is no forfeiture rate applied to options granted to non-employee directors and executive employees because their pre-vesting forfeitures are anticipated to be highly unlikely. As individual options become fully vested, stock-based compensation expense is adjusted to recognize actual forfeitures. A summary of the options granted during 2020 and the total number of options outstanding as of December 31, 2020 and changes since January 1, 2020 are set forth below: Number of Shares Outstanding (In thousands) Weighted Average Exercise Price Weighted Average Remaining Contractual Life (In years) Aggregate Intrinsic Value (In thousands) Outstanding, January 1, 2020 2,637 $ 15.18 4.65 $ 506 Granted 955 $ 11.67 — — Exercised (117) $ 10.87 — — Forfeited (157) $ 14.96 — — Outstanding, December 31, 2020 3,318 $ 14.33 4.67 $ 10,667 Vested or expected to vest, December 31, 2020 3,285 $ 14.33 4.64 $ 10,537 Exercisable, December 31, 2020 2,397 $ 14.59 3.85 $ 6,993 The weighted average grant date fair value of options granted during 2020 and 2019 was $4.79 and $4.14, respectively. The total fair value of shares vested in 2020 and 2019 was $2.1 million and $1.3 million, respectively. The Company recognized $3.8 million and $1.2 million in expense related to stock options for the years ended December 31, 2020 and 2019, respectively. As of December 31, 2020, there was approximately $1.8 million of unrecognized compensation expense related to unvested stock options. This expense is expected to be recognized over a weighted-average period of approximately 1.5 years. Employee Stock Purchase Plan In May 2015, the Company adopted the SeaSpine Holdings Corporation 2015 Employee Stock Purchase Plan, which was amended in November 2018, as described below (as amended, the ESPP). Under the ESPP, eligible employees may purchase shares of the Company’s common stock through payroll deductions of up to 15% of eligible compensation during an offering period. Generally, each offering period will be for 24 months as determined by the Company's board of directors. There are four six-month purchase periods in each offering period for contributions to be made and to be converted into shares at the end of the purchase period. In no event may an employee purchase more than 2,500 shares per purchase period based on the closing price on the first trading date of an offering period or more than $25,000 worth of stock during any calendar year. The purchase price for shares to be purchased under the ESPP is 85% of the lesser of the market price of the Company's common stock on the first trading date of an offering period or on any purchase date during an offering period (June 30 or December 31). Subject to stockholder approval, on and effective as of November 2, 2018, the Company's board of directors approved an amendment to the ESPP pursuant to which the share reserve under the ESPP would increase from 400,000 shares to 800,000 shares. The Company's stockholders approved that amendment in May 2019. On December 8, 2020, the Company's board of directors approved the issuance of an additional 500,000 shares of common stock under the ESPP, subject to stockholder approval. The ESPP is intended to qualify as an “employee stock purchase plan” within the meaning of Section 423 of the Internal Revenue Code of 1986, as amended (the IRC). The ESPP contains a restart feature, such that if the market price of the stock at the end of any six-month purchase period is lower than the market price at the original grant date of an offering period, that offering period will terminate after that purchase date, and a new two-year offering period will commence on the January 1 or July 1 immediately following the date the original offering period terminated. The restart feature was triggered on the purchase date that occurred on June 30, 2019, such that the offering period that commenced on January 1, 2019 was terminated, and a new two-year offering period commenced on July 1, 2019 and would end on June 30, 2021. This restart feature was triggered again on the purchase date that occurred on December 31, 2019, such that the offering periods that commenced on each of July 1, 2018 and July 1, 2019 were terminated, and a new two-year offering period commenced on January 1, 2020 and would end on December 31, 2021. This restart feature was triggered again on the purchase date that occurred on June 30, 2020, such that the offering period that commenced on January 1, 2020 was terminated, and a new two-year offering period commenced on July 1, 2020 and will end on June 30, 2022. The Company applied share-based payment modification accounting to the awards that were initially valued at the grant date to determine the amount of any incremental fair value associated with the modified awards. The impact to stock-based compensation expense for modifications during the year ended December 31, 2020 was immaterial. During the years ended December 31, 2020 and 2019, there were 153,302 and 119,602 shares of common stock, respectively, purchased under the ESPP. The Company recognized $0.9 million and $0.7 million in expense related to the ESPP for the years ended December 31, 2020 and 2019, respectively. As of December 31, 2020, 127,160 shares were available under the ESPP for future issuance. The Company estimates the fair value of shares issued to employees under the ESPP using the Black-Scholes-Merton option-pricing model. The following weighted average assumptions were used in the calculation of fair value of shares under the ESPP at the grant date for the periods indicated: December 31, 2020 2019 Expected dividend yield 0 % 0 % Risk-free interest rate 0.7 % 1.4 % Expected volatility 24.6 % 21.9 % Expected term (in years) 0.7 0.7 |
LEASE
LEASE | 12 Months Ended |
Dec. 31, 2020 | |
Leases [Abstract] | |
Lessee, Operating Leases | LEASES The impact of the adoption of Topic 842 to the Company's applicable balance sheet items as of January 1, 2020 is presented in the table below. The standard did not have a material impact to the Company's unaudited condensed consolidated statements of operations or comprehensive loss or cash flows. (in thousands) December 31, 2019 Impact of Adoption of ASC 842 January 1, 2020 ASSETS Right of use assets $ — $ 9,059 $ 9,059 Total assets $ 141,718 $ 9,059 $ 150,777 LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities: Other accrued expenses and current liabilities 5,444 (138) 5,306 Current portion of operating lease liabilities — 2,080 2,080 Total current liabilities 30,478 1,942 32,420 Operating lease liabilities, net of current portion — 8,367 8,367 Other liabilities 1,480 (1,250) 230 Total liabilities $ 31,958 $ 9,059 $ 41,017 Total stockholders' equity $ 109,760 $ — $ 109,760 Total liabilities and stockholders' equity $ 141,718 $ 9,059 $ 150,777 The Company’s lease portfolio only includes operating leases. As of December 31, 2020, the weighted average remaining lease term of these operating leases was 5.3 years and the weighted average discount rate was 6.5%. For each of the years ended December 31, 2020 and 2019, lease expense, which represents expense from operating leases, was $2.1 million. A summary of the Company's remaining lease liabilities at December 31, 2020 are as follows: Payments Due by Calendar Year (In thousands) 2021 $ 2,644 2022 2,243 2023 1,568 2024 1,374 2025 1,409 Thereafter 1,869 Total undiscounted value of lease liabilities $ 11,107 Less: present value adjustment (1,737) Less: short-term leases not capitalized (421) Present value of lease liabilities 8,949 Less: current portion of lease liability (2,147) Operating lease liability, less current portion $ 6,802 |
INCOME TAXES
INCOME TAXES | 12 Months Ended |
Dec. 31, 2020 | |
Income Tax Disclosure [Abstract] | |
INCOME TAXES | INCOME TAXES The Company is subject to income taxes in the U.S., Switzerland and France. Income taxes are accounted for under the asset and liability method. Deferred income tax assets and liabilities are calculated based on the difference between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases using the enacted income tax rates expected to be in effect during the years in which the temporary differences are expected to reverse. Valuation allowances are recorded to reduce deferred tax assets when it is more likely than not that a tax benefit will not be realized. Significant judgment is required in determining whether a valuation allowance should be recorded against deferred tax assets. In assessing the need for a valuation allowance, management considers all available evidence for each jurisdiction including past operating results, estimates of future taxable income and the feasibility of ongoing tax planning strategies. In the event that the Company changes its determination as to the amount of deferred tax assets that can be realized, the Company will adjust its valuation allowance with a corresponding impact to income tax expense in the period in which such determination is made. Income Tax Provision Loss before income taxes consisted of: Year Ended December 31, 2020 2019 (In thousands) United States operations $ (42,251) $ (39,342) Foreign operations (712) 422 $ (42,963) $ (38,920) A reconciliation of the U.S. federal statutory rate to the Company’s effective tax rate is: Year Ended December 31, 2020 2019 Federal statutory rate 21.0% 21.0% Increase (decrease) in income taxes resulting from: State income taxes, net of federal tax benefit 2.0% 2.7% Foreign operations (0.3)% (0.8)% Changes in valuation allowances (22.3)% (24.7)% Uncertain tax positions —% 0.1% Research and development credit 0.6% 0.2% Other (1.5)% 0.6% Effective tax rate (0.5)% (0.9)% The provision/(benefit) for income taxes consisted of: Year Ended December 31, 2020 2019 (In thousands) Current: Federal $ — $ (27) State 87 59 Foreign 28 39 Total current $ 115 $ 71 Deferred: Federal — — State — — Foreign 103 285 Total deferred $ 103 $ 285 Provision for income taxes $ 218 $ 356 The income tax effects of significant temporary differences that give rise to deferred tax assets and liabilities, shown before jurisdictional netting, are presented below: Year Ended December 31, 2020 2019 (In thousands) Deferred tax assets: Doubtful accounts $ 47 $ 27 Inventory related items 12,317 10,508 Tax credits 563 319 Accrued vacation 536 369 Accrued bonus 517 1,099 Stock compensation 4,947 4,431 Net operating loss carryforwards 45,744 38,149 Intangible and fixed assets 10,740 10,806 Other 704 1,000 Total deferred tax assets 76,115 66,708 Less valuation allowance (75,147) (65,576) Deferred tax assets after valuation allowance $ 968 $ 1,132 Deferred tax liabilities: Other 927 988 Total deferred tax liabilities $ 927 $ 988 Net deferred tax assets $ 41 $ 144 At December 31, 2020, the Company had net operating loss carryforwards of $187.7 million for federal and state income tax purposes. The Company also had net operating loss carryforwards of $0.2 million for foreign income tax purposes. These loss carryforwards begin to expire in 2021 for foreign income tax purposes and in 2027 for federal and state income tax purposes, and continue to expire through 2039. The Company’s net operating loss carryforwards generated after 2017 for federal income tax purposes do not expire. The tax expense recorded for net operating losses, net of valuation allowance, was $0.1 million which relates only to foreign net operating losses. At December 31, 2019, the Company had net operating loss carryforwards of $156.3 million for federal and state income tax purposes. The Company also had net operating loss carryforwards of $0.6 million for foreign income tax purposes. These loss carryforwards begin to expire in 2021 for foreign income tax purposes and in 2027 for federal and state income tax purposes, and continue to expire through 2039. The Company’s net operating loss carryforwards generated after 2017 for federal income tax purposes do not expire. The tax expense recorded for net operating losses, net of valuation allowance, was $0.3 million which relates only to foreign net operating losses. The valuation allowance relates to deferred tax assets for certain items that will be deductible for income tax purposes under very limited circumstances and for which the Company believes it is not more likely than not that it will realize the associated tax benefit. However, in the event that the Company determines that it would be able to realize more or less than the recorded amount of net deferred tax assets, an adjustment to the deferred tax asset valuation allowance would be recorded in the period such a determination is made. In assessing the realizability of deferred tax assets, management considers whether it is more-likely-than-not that some portion of all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. Management considers the scheduled reversal of deferred tax liabilities (including the impact of available carryback and carryforward periods), projected future taxable income, and tax planning strategies in making this assessment. Based upon the levels of historical taxable income, projections of future taxable income and the reversal of deferred tax liabilities over the periods in which the deferred tax assets are deductible, management believes it is more-likely-than-not that the Company will realize the benefits of these deductible differences, net of the existing valuation allowance. The amount of deferred tax asset considered realizable, however, could change in the near term if estimates which require significant judgment of future taxable income during the carryforward period are increased or decreased. A reconciliation of the Company’s uncertain tax benefits is as follows: Year Ended December 31, 2020 2019 (In thousands) Balance, beginning of year $ 319 $ 255 Gross increases: Prior years’ tax positions 74 15 Additions to tax positions in prior years due to spin-off — — Current year tax positions 170 75 Gross decreases: Settlements — — Statute of limitations lapses — (26) Balance, end of year $ 563 $ 319 The Company recognizes interest and penalties relating to uncertain tax positions in income tax expense. The amounts recorded in 2020 and 2019 were not significant. The Company files income tax returns as prescribed by tax laws of the jurisdictions in which it operates. In the normal course of business, the Company is subject to examination by federal, state, local and foreign jurisdictions where applicable based on the statute of limitations that apply in each jurisdiction. The Company has no open income tax audits with any taxing authority as of December 31, 2020. The Company is still subject to income tax examinations by U.S. federal and state tax authorities for the years 2016 through 2020. Open years for foreign jurisdictions are from 2015 through 2020. However, to the extent allowed by law, the tax authorities may have the right to examine prior periods where net operating losses were generated and carried forward, and make adjustments up to the amount of the net operating loss carryforward amount. |
COMMITMENTS AND CONTINGENCIES
COMMITMENTS AND CONTINGENCIES | 12 Months Ended |
Dec. 31, 2020 | |
Commitments and Contingencies Disclosure [Abstract] | |
COMMITMENTS AND CONTINGENCIES | COMMITMENTS AND CONTINGENCIESIn consideration for certain technology, manufacturing, distribution, and selling rights and licenses granted to the Company, the Company agreed to pay royalties on sales of certain products sold by the Company. Except for the royalties paid to NLT, the royalties the Company paid are included as a component of cost of goods sold in the consolidated statements of operations. The Company is subject to various legal proceedings in the ordinary course of its business with respect to its products, its current or former employees, and its commercial relationships, some of which have been settled by the Company. In the opinion of management, such proceedings are either adequately covered by insurance or otherwise indemnified, or are not expected, individually or in the aggregate, to result in a material adverse effect on the Company's financial condition. However, it is possible that the Company's results of operations, financial position and cash flows in a particular period could be materially affected by these contingencies. The Company accrues for loss contingencies when it is deemed probable that a loss has been incurred and that loss is estimable. The amounts accrued are based on the full amount of the estimated loss before considering insurance proceeds, and do not include an estimate for legal fees expected to be incurred in connection with the loss contingency. While uncertainty exists, the Company does not believe there are any pending legal proceedings that would have a material impact on the Company’s financial position, cash flows or results of operations. |
SEGMENT AND GEOGRAPHIC INFORMAT
SEGMENT AND GEOGRAPHIC INFORMATION | 12 Months Ended |
Dec. 31, 2020 | |
Segment Reporting [Abstract] | |
SEGMENT AND GEOGRAPHIC INFORMATION | SEGMENT AND GEOGRAPHIC INFORMATION Management assessed its segment reporting based on how it internally manages and reports the results of its business to its chief operating decision maker. Management reviews financial results, manages the business and allocates resources on an aggregate basis. Therefore, financial results are reported in a single operating segment: the development, manufacture and marketing of orthobiologics and of spinal implants. The Company reports revenue in two product categories: orthobiologics and spinal implants. Orthobiologics products consist of a broad range of advanced and traditional bone graft substitutes that are designed to improve bone fusion rates following surgery. The spinal implant portfolio consists of an extensive line of products for minimally invasive surgery, complex spine, deformity and degenerative procedures. The Company attributes revenues to geographic areas based on the location of the customer. The following table disaggregates revenue by major sales channel for each of the periods presented (in thousands): Year Ended December 31, 2020 United States International Total (In thousands) Orthobiologics $ 71,346 $ 7,037 $ 78,383 Spinal implants $ 67,550 $ 8,412 75,962 Total revenue, net $ 138,896 $ 15,449 $ 154,345 Year Ended December 31, 2019 United States International Total (In thousands) Orthobiologics $ 73,543 $ 7,756 $ 81,299 Spinal implants $ 68,308 $ 9,476 $ 77,784 Total revenue, net $ 141,851 $ 17,232 $ 159,083 |
EMPLOYEE BENEFIT PLAN
EMPLOYEE BENEFIT PLAN | 12 Months Ended |
Dec. 31, 2020 | |
Retirement Benefits [Abstract] | |
EMPLOYEE BENEFIT PLAN | EMPLOYEE BENEFIT PLANThe Company has a defined contribution savings plan under section 401(k) of the IRC. The plan covers substantially all employees. The Company matches employee contributions made to the plan according to a specified formula. The Company’s matching contributions totaled approximately $1.1 million and $0.6 million for the years ended 2020 and 2019, respectively. |
SELECTED QUARTERLY INFORMATION
SELECTED QUARTERLY INFORMATION - UNAUDITED | 12 Months Ended |
Dec. 31, 2020 | |
Quarterly Financial Information Disclosure [Abstract] | |
SELECTED QUARTERLY INFORMATION - UNAUDITED | SELECTED QUARTERLY INFORMATION - UNAUDITED First Quarter Second Quarter Third Quarter Fourth Quarter (In thousands, except per share data) Total revenue, net: 2020 $ 36,111 $ 28,589 $ 43,209 $ 46,436 2019 36,150 39,306 39,888 43,739 Gross profit: 2020 $ 22,299 $ 16,930 $ 29,135 $ 29,140 2019 22,571 24,989 25,481 28,063 Net loss: 2020 $ (12,551) $ (13,713) $ (6,574) $ (10,343) 2019 (8,989) (12,036) (9,663) (8,588) Basic/diluted net loss per common share (1) : 2020 $ (0.48) $ (0.50) $ (0.24) $ (0.37) 2019 (0.48) (0.64) (0.51) (0.45) (1) Per common share amounts for the quarters and full years have been calculated separately. Accordingly, quarterly amounts do not necessarily add to the annual amount because of differences in the weighted average common shares outstanding during each period principally due to the effect of the Company’s issuing or canceled shares of its common stock during the year. |
SCHEDULE II - VALUATION AND QUA
SCHEDULE II - VALUATION AND QUALIFYING ACCOUNTS | 12 Months Ended |
Dec. 31, 2020 | |
SEC Schedule, 12-09, Valuation and Qualifying Accounts [Abstract] | |
SCHEDULE II - VALUATION AND QUALIFYING ACCOUNTS | SCHEDULE II — VALUATION AND QUALIFYING ACCOUNTS Balance at Beginning of Period Charged to Costs and Expenses Charged to Other Accounts Additions/Deductions Balance at End of Period Description (In thousands) Year ended December 31, 2020: Allowance for doubtful accounts and other credits $ 111 $ — $ — $ 81 $ 192 Inventory Reserves 32,237 6,903 — (1,125) 38,015 Deferred tax asset valuation allowance 65,576 9,571 — — 75,147 Year ended December 31, 2019: Allowance for doubtful accounts and sales returns and other credits $ 850 $ 20 $ (417) $ (342) $ 111 Inventory Reserves 29,309 4,747 — (1,819) 32,237 Deferred tax asset valuation allowance 55,954 9,622 — — 65,576 |
SUMMARY OF SIGNIFICANT ACCOUN_2
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) | 12 Months Ended |
Dec. 31, 2020 | |
Accounting Policies [Abstract] | |
Use of Estimates | Use of Estimates Preparing consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent liabilities, and the reported amounts of revenues and expenses. Significant estimates affecting amounts reported or disclosed in the consolidated financial statements include allowances for doubtful accounts receivable and sales returns and other credits, net realizable value of inventories, discount rates and estimated projected cash flows used to value and test impairments of identifiable intangible and long-lived assets, assumptions related to the timing and probability of product launch dates, discount rates matched to the estimated timing of payments, probability of success rates and discount adjustments on the related cash flows for contingent considerations in business combinations, depreciation and amortization periods for identifiable intangible and long-lived assets, computation of taxes, valuation allowances recorded against deferred tax assets, the valuation of stock-based compensation and loss contingencies. These estimates are based on historical experience and on various other assumptions believed to be reasonable under the current circumstances. Actual results could differ from these estimates. The full extent to which the COVID-19 pandemic will directly or indirectly impact the Company's business, results of operations and financial condition, including revenues, expenses, manufacturing, research and development costs and employee-related compensation, will depend on future developments that are highly uncertain, including as a result of new information that may emerge concerning COVID-19 and the actions taken to contain it or treat COVID-19, as well as the economic impact on local, regional, national and international customers and markets. The Company has made estimates of the impact of the pandemic within its financial statements and there may be changes to those estimates in future periods. Actual results may differ from these estimates. |
Cash and Cash Equivalents | Cash and Cash Equivalents The Company considers all highly liquid investments with a maturity of 90 days or less at the date of purchase to be cash equivalents. Cash and cash equivalents include cash readily available in checking and money market accounts. |
Fair Value of Financial Instruments | Fair Value of Financial Instruments The carrying amounts of cash, cash equivalents, receivables, accounts payable and accrued expenses at December 31, 2020 and 2019, are considered to approximate fair value because of the short-term nature of those items. The Company measures certain assets and liabilities in accordance with authoritative guidance which requires fair value measurements to be classified and disclosed in one of the following three categories: Level 1: Quoted prices (unadjusted) in active markets that are accessible at the measurement date for assets or liabilities. Level 2: Observable prices that are based on inputs not quoted on active markets, but corroborated by market data. Level 3: Unobservable inputs are used when little or no market data is available. The carrying amounts of contingent consideration liabilities at December 31, 2020 and 2019 related to business combinations are measured at fair value on a recurring basis, and are classified within Level 3 of the fair value hierarchy because they use significant unobservable inputs. See Note 5, "Fair Value Measurements" , below, for further information. |
Trade Accounts Receivable and Allowances | Trade Accounts Receivable and Allowances Trade accounts receivable in the accompanying consolidated balance sheets are presented net of allowances for doubtful accounts and sales returns and other credits. The Company grants credit to customers in the normal course of business, but generally does not require collateral or any other security to support its receivables. The Company evaluates the collectability of accounts receivable based on a combination of factors. In circumstances where a specific customer is unable to meet its financial obligations to the Company, a provision to the allowances for doubtful accounts is recorded to reduce the net recognized receivable to the amount that is reasonably expected to be collected. For all other customers, a provision to the allowances for doubtful accounts is recorded based on factors including the length of time the receivables are past due, the current business environment and the Company’s historical experience. Provisions to the allowances for doubtful accounts are recorded to general and administrative expenses. Account balances are charged off against the allowance when it is probable that the receivable will not be recovered. |
Inventories | Inventories Inventories, consisting of purchased materials, direct labor and manufacturing overhead, are stated at the lower of cost, the value determined by the first-in, first-out method, or net realizable value. At each balance sheet date, the Company evaluates inventories for excess quantities, obsolescence or shelf life expiration. This evaluation includes analysis of the Company's current and future strategic plans, historical sales levels by product, projections of future demand, the risk of technological or competitive obsolescence for products, general market conditions, a review of the shelf life expiration dates for products, as well as the feasibility of reworking or using excess or obsolete products or components in the production or assembly of other products that are not obsolete or for which there are not excess quantities in inventory. To the extent that management determines there are excess or obsolete inventory or quantities with a shelf life that is too near its expiration for the Company to reasonably expect that it can sell those products prior to their expiration, the Company adjusts the carrying value to estimated net realizable value. The Company capitalizes inventory costs associated with certain products prior to regulatory approval, based on management’s judgment of probable economic benefit. The Company could be required to expense previously capitalized costs related to pre-approval inventory upon a change in such judgment, due to, among other potential factors, a denial or delay of approval by necessary regulatory bodies or a decision by management to discontinue the related development program. No material amounts were capitalized at December 31, 2020 or 2019. |
Property, Plant and Equipment | Property, Plant, and Equipment Property, plant and equipment are stated at historical cost less accumulated depreciation and any impairment charges. The Company provides for depreciation using the straight-line method over the estimated useful lives of the assets. Leasehold improvements are amortized over the lesser of the lease term or the useful life. The cost of major additions and improvements is capitalized, while maintenance and repair costs that do not improve or extend the lives of the respective assets are charged to operations as incurred. The cost of computer software obtained for internal use is accounted for in accordance with the Codification 350-40, Internal-Use Software. The cost of purchased spinal instruments that the Company consigns to hospitals and independent sales agents to support surgeries is initially capitalized as construction in progress. The amount is then either reclassified to spinal instruments and sets and depreciation is initiated when instruments are put together in a newly built set with spinal implants, or directly expensed for the instruments used to replace damaged instruments in an existing set. The depreciation expense and direct expense for replacement instruments are recorded in selling and marketing expense. |
Business Combinations | Business Combinations The purchase price of each acquisition is allocated to the net assets acquired based on estimates of their fair values at the date of the acquisition. Any purchase price in excess of these net assets is recorded as goodwill, and any fair value of these net assets, excluding goodwill, in excess of the purchase price is recorded as a bargain purchase gain. The allocation of purchase price in certain cases may be subject to revision based on the final determination of fair values during the measurement period, which may be up to one year from the acquisition date. |
Identifiable Intangible Assets | Identifiable Intangible Assets Identifiable intangible assets are initially recorded at fair value at the time of acquisition, generally using an income or cost approach. The Company capitalizes costs incurred to renew or extend the term of recognized intangible assets and amortizes those costs over their expected useful lives. |
Impairment of Long-Lived Assets | Impairment of Long-Lived Assets Long-lived assets held and used by the Company, including property, plant and equipment and intangible assets, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. For purposes of evaluating the recoverability of long-lived assets to be held and used, a recoverability test is performed using projected undiscounted net cash flows applicable to the long-lived assets. If an impairment exists, the amount of such impairment is calculated based on the estimated fair value of the asset. Impairments to long-lived assets to be disposed of are recorded based upon the difference between the carrying value and the fair value of the applicable assets. The Company determined an impairment exists for certain intangible assets during the year ended December 31, 2020 and 2019. Excluding the impairment of spinal instruments, there was no impairment of tangible long-lived assets in any of the periods presented. See Note 4, "Balance Sheet Details" , below, for additional information. |
Foreign Currency | Foreign Currency The Company generates revenues outside the United States in multiple foreign currencies including euros, Swiss francs and in U.S. dollar-denominated transactions conducted with customers who generate revenue in currencies other than the U.S. dollar. The Company also incurs operating expenses in euros and Swiss francs. All assets and liabilities of foreign subsidiaries which have a functional currency other than the U.S. dollar are translated at the rate of exchange at year-end, while elements of the income statement are translated at the average exchange rates in effect during the year. The net effect of these translation adjustments is shown as a component of accumulated other comprehensive income. These currency translation adjustments are not currently adjusted for income taxes as they relate to permanent investments in non-U.S. subsidiaries. Foreign currency transaction gains and losses are reported in other income (expense), net. |
Income Taxes | Income TaxesThe Company recognizes tax benefits in its financial statements when its uncertain tax positions are more likely than not to be sustained upon audit. The amount recognized is measured as the largest amount of benefit that is greater than 50 percent likely of being realized upon ultimate settlement. The Company recognizes deferred tax assets for deductible temporary differences, operating loss carryforwards and tax credit carryforwards. Deferred tax assets are reduced by valuation allowance if it is more likely than not that some portion, or all, of the deferred tax assets will not be realized. |
Revenue Recognition | Revenue Recognition Net sales are derived primarily from the sale of orthobiologics and spinal implant products globally. Revenue is recognized when obligations under the terms of a contract with the Company's customer are satisfied which occurs with the transfer of control of the Company's products. This occurs either upon shipment or delivery of goods, depending on whether the contract is Free on Board (FOB) origin or FOB destination, or, in other situations such as consignment arrangements, when the products are used in a surgical procedure (implanted in a patient). Revenue is measured as the amount of consideration the Company expects to receive in exchange for transferring products to a customer (transaction price). To the extent that the transaction price includes variable consideration, such as discounts, list price discounts, rebates, volume discounts and customer payment penalties, the Company estimates the amount of variable consideration that should be included in the transaction price utilizing the most likely amount method. Variable consideration is included in the transaction price if, in the Company’s judgment, it is probable that a significant future reversal of cumulative revenue under the contract will not occur. Estimates of variable consideration and determination of whether to include estimated amounts in the transaction price are based largely on an assessment of the Company’s anticipated performance and all information (historical, current and forecasted) that is reasonably available. The Company reduces revenue by estimates of potential future product returns and other allowances. Provisions for product returns and other allowances are recorded as a reduction to revenue in the period sales are recognized. The Company estimates the amount of sales returns and allowances that will eventually be incurred. Certain contracts with stocking distributors contain provisions requiring the Company to repurchase inventory upon termination of the contract or discontinuation of a product line. Included in the sales returns reserve within other current liabilities is an estimate of repurchases that are likely to be made under these provisions. Management analyzes sales programs that are in effect, contractual arrangements, market acceptance and historical trends when evaluating the adequacy of sales returns and allowance accounts. In certain sales arrangements, the Company fulfills its obligations and bills the customer for the products prior to the shipment of goods. The Company allocates the transaction price to the multiple performance obligations under these contracts, including delivery of the products and the third-party logistics (3PL) performance obligations. Revenue related to product sales under these arrangements is not recognized until the Company delivers the products to the customer’s dedicated space within the Company’s facility, at which point the customer obtains control of the products. Revenue from the related 3PL obligations consists of revenue from storage of products which is recognized ratably over the service period, and revenue from shipping services which is recognized upon performance of such obligation. Product royalties account for less than 1% of total revenue for any of the periods presented, and are estimated and recognized in the same period that the royalty-based products are sold by licensees. The Company estimates and recognizes royalty revenue based upon communication with licensees, historical information and expected sales trends. Differences between actual revenues and estimated royalty revenues are adjusted in the period in which they become known, which is typically the following quarter. Historically, such adjustments have not been material. |
Shipping and Handling Fees and Costs | Shipping and Handling Fees and Costs The Company has elected to account for shipping and handling activities as fulfillment activities. As such, the Company does not evaluate shipping and handling as promised services to its customers. Shipping and handling costs of $2.5 million for shipments of loaned spinal implants and instrumentation sets and costs incurred for internal movement of inventory were recorded in selling and marketing expense during each of the years ended December 31, 2020 and 2019, respectively. |
Research and Development | Research and Development Research and development costs, including salaries, stock-based compensation, depreciation, consultant, clinical study, product registration and other external fees, and facility costs directly attributable to research and development activities, are expensed in the period in which they are incurred. |
Stock-Based Compensation | Stock-Based Compensation The Company's stock-based compensation has been recognized through the consolidated statement of operations and the Company's additional paid-in capital account on the consolidated balance sheet. The Company recognizes the expense related to the fair value of their stock-based compensation awards. Stock-based compensation expense for stock option awards was based on the fair value on the grant date using the Black-Scholes-Merton option pricing model. The fair value of restricted stock granted prior to the spin-off was based on the Integra’s stock price at the grant date, and the fair value of restricted stock granted after the spin-off was based on the Company's stock price at the grant date. The long form method was used in the determination of the windfall tax benefit. The stock-based compensation is initially measured at the fair value of the awards on the grant date and is then recognized on a ratable basis in the financial statements over the requisite service period of the award. Stock-based compensation expense was $10.4 million in 2020 and $7.8 million in 2019. |
Concentration of Credit Risk | Concentration of Credit Risk Financial instruments, which potentially subject the Company to concentrations of credit risk, consist principally of cash, which is held at major financial institutions, and trade receivables. The Company’s products are sold on an uncollateralized basis and on credit terms based upon a credit risk assessment of each customer. A portion of the Company’s trade receivables to customers outside the United States includes sales to foreign stocking distributors, who then sell to government owned or supported healthcare systems. The ongoing economic conditions in certain European countries, especially Greece, Ireland, Italy, Portugal and Spain remain uncertain. Accounts receivable from customers in these countries are not a material amount of the Company’s overall receivables. None of the Company’s customers accounted for 10% or more of the net sales or accounts receivable for any of the periods presented. |
Recently Issued and Adopted Accounting Standards | Recent Accounting Standards Not Yet Adopted In June 2016, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU or Update) No. 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments , which requires credit losses on most financial assets measured at amortized cost, including trade receivables, and certain other instruments to be measured using an expected credit loss model, referred to as the current expected credit loss (CECL) model. Under this model, entities will estimate credit losses over the entire contractual term of the instrument. The new standard will be effective for the Company beginning January 1, 2023. The FASB subsequently issued other related ASUs that amend ASU No. 2016-13 to provide clarification and additional guidance. The Company is evaluating the impact of this standard on its consolidated financial statements. In August 2018, the FASB issued Update No. 2018-15, Intangibles-Goodwill and Other-Internal Use Software (Subtopic 350-40) . The amendments in this Update align the requirements for capitalizing implementation costs incurred in a hosting arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software (and hosting arrangements that include an internal-use software license). The new standard will be effective for the Company beginning on January 1, 2021. Early adoption is permitted. The adoption of this new standard is not expected to have a material impact on its consolidated financial statements. In April 2019, the FASB issued Update No. 2019-04, Codification Improvements to Topic 326, Financial Instruments-Credit Losses, Topic 815, Derivatives and Hedging, and Topic 825, Financial Instruments . This Update includes several amendments to the FASB Accounting Standards Codification (Codification) intended to clarify, improve, or correct errors therein. Some amendments do not require transition guidance and are effective upon issuance. The amendments requiring transition guidance have the same effective date as Update No. 2016-13 and will be effective for the Company beginning on January 1, 2023. The Company is evaluating the impact of this standard on its consolidated financial statements. Recently Adopted Accounting Standards In February 2016, the FASB issued Update No. 2016-02, Leases (Topic 842). The new standard requires lessees to recognize lease liabilities and corresponding right-of-use assets for all leases with lease terms of greater than twelve months. It also changes the definition of a lease and expands the disclosure requirements of lease arrangements. The new standard must be adopted using the modified retrospective approach. In July 2018, the FASB issued Update No. 2018-10, Codification Improvements to Topic 842 (Leases) and Update No. 2018-11, Leases (Topic 842): Targeted Improvements. In March 2019, the FASB issued Update No. 2019-01, Leases (Topic 842): Codification Improvements. In November 2019, the FASB issued Update No. 2019-10, Financial Instruments - Credit Losses (Topic 326), Derivatives and Hedging (Topic 815), and Leases (Topic 842): Effective Dates, which modifies the effective dates for Topic 842. The amendments in Updates Nos. 2018-10, 2018-11, 2019-01, and 2019-10 provide additional clarification and implementation guidance on certain aspects of Topic 842 and have the same effective date and transition requirements as ASU 2019-10. The Company early adopted the new standard beginning on January 1, 2020. The Company adopted the new standard electing the optional transition method that allows for a cumulative-effect adjustment in the period of adoption and did not restate prior periods. The Company applied the transition package of practical expedients allowed by the standard. As a result of the Company’s adoption of the new standard, the Company recorded right-of-use assets and lease liabilities of $9.1 million and $10.5 million, respectively, for existing operating leases in the consolidated balance sheets at January 1, 2020. Additionally, the Company reversed $1.4 million of deferred rent liabilities previously recorded under the previous accounting guidance. The adoption of this new standard had no material impact on its consolidated results of operations or cash flows. In June 2018, the FASB issued Update No. 2018-07, Compensation-Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting . This Update requires an entity to apply the requirements of Topic 718 to nonemployee awards except for specific guidance on inputs to an option pricing model and the attribution of cost (that is, the period of time over which share-based payment awards vest and the pattern of cost recognition over that period). The amendments specify that Topic 718 applies to all share-based payment transactions in which a grantor acquires goods or services to be used or consumed in a grantor’s own operations by issuing share-based payment awards. The amendments also clarify that Topic 718 does not apply to share-based payments used to effectively provide (1) financing to the issuer or (2) awards granted in conjunction with selling goods or services to customers as part of a contract accounted for under Topic 606. The new standard was effective for the Company beginning on January 1, 2020. The adoption of this new standard had no material impact on its consolidated financial statements. In August 2018, the FASB issued Update No. 2018-13, Fair Value Measurement (Topic 820)-Disclosure Framework-Changes to the Disclosure Requirements for Fair Value Measurement . The amendments in this Update modify the disclosure requirements on fair value measurements in Topic 820 based on the concepts in the Concepts Statement including the consideration of costs and benefits. The new standard was effective for the Company beginning on January 1, 2020. The adoption of this new standard had no material impact on its consolidated financial statements. In March 2020, the FASB issued Update No. 2020-04, Reference Rate Reform (Topic 848), Facilitation of the Effects of Reference Rate Reform on Financial Reporting . The amendments in this Update apply only to contracts, hedging relationships, and other transactions that reference LIBOR, or another reference rate expected to be discontinued, due to the reference rate reform. The new standard was effective for the Company beginning March 12, 2020. The adoption of this new standard had no material impact on its consolidated financial statements. |
Net Loss Per Share | Net Loss Per Share Basic and diluted net loss per share was calculated using the weighted-average number of shares of common stock outstanding |
Lessee, Leases | Leases The Company determines if an arrangement is a lease at inception. The Company's leases primarily relate to administrative, manufacturing, research, and distribution facilities and various manufacturing, office and transportation equipment. Lease assets represent the Company's right to use an underlying asset for the lease term and lease liabilities represent the obligation to make lease payments arising from the lease. Lease assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. As the Company's leases do not provide an implicit rate, the Company's incremental borrowing rate is used as a discount rate, based on the information available at the commencement date, in determining the present value of lease payments. Lease assets also include the impact of any prepayments made and are reduced by impact of any lease incentives. The Company made an accounting policy election for short-term leases, such that the Company will not recognize a lease liability or lease asset on its balance sheet for leases with a lease term of twelve months or less as of the commencement date. Rather, any short-term lease payments will be recognized as an expense on a straight-line basis over the lease term. The current period short-term lease expense reasonably reflects the Company's short-term lease commitments. The Company made a policy election for all classifications of leases to combine lease and non-lease components and to account for them as a single lease component. Variable lease payments are excluded from the lease liability and recognized in the period in which the obligation is incurred. Additionally, lease terms may include options to extend or terminate the lease when it is reasonably certain the Company will exercise the option. |
BALANCE SHEET DETAILS (Tables)
BALANCE SHEET DETAILS (Tables) | 12 Months Ended |
Dec. 31, 2020 | |
Balance Sheet Related Disclosures [Abstract] | |
Schedule of Inventory, Net | Inventories consisted of: December 31, 2020 December 31, 2019 (In thousands) Finished goods $ 37,689 $ 30,042 Work in process 10,087 10,847 Raw materials 6,265 6,266 $ 54,041 $ 47,155 |
Schedule of Property, Plant and Equipment | Property, plant and equipment balances and corresponding useful lives were as follows: December 31, 2020 December 31, 2019 Useful Lives (In thousands) Leasehold improvements $ 5,976 $ 5,878 Shorter of lease term or useful life Machinery and production equipment 9,577 8,562 3-10 years Spinal instruments and sets 30,275 25,511 4-5 years Information systems and hardware 7,554 7,442 3-7 years Furniture and fixtures 1,640 1,412 3-5 years Construction in progress 12,645 9,716 Total 67,667 58,521 Less accumulated depreciation and amortization (36,245) (32,770) Property, plant and equipment, net $ 31,422 $ 25,751 |
Schedule of Components of Identifiable Intangible Assets | The components of the Company’s identifiable intangible assets were: December 31, 2020 Weighted Cost Accumulated Net (In thousands) Product technology 12 years $ 32,891 $ (29,766) $ 3,125 Customer relationships 12 years 56,830 (46,072) 10,758 Trademarks/brand names — 300 (300) — $ 90,021 $ (76,138) $ 13,883 December 31, 2019 Weighted Cost Accumulated Net (In thousands) Product technology 12 years $ 34,158 $ (28,912) $ 5,246 Customer relationships 12 years 56,830 (42,903) 13,927 Trademarks/brand names — 300 (300) — $ 91,288 $ (72,115) $ 19,173 |
FAIR VALUE MEASUREMENTS (Tables
FAIR VALUE MEASUREMENTS (Tables) | 12 Months Ended | |
Dec. 31, 2020 | Dec. 31, 2019 | |
Fair Value Disclosures [Abstract] | ||
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis | The fair values of the Company’s assets and liabilities, including contingent consideration liabilities, are measured at fair value on a recurring basis, and are determined under the fair value categories as follows (in thousands): Total Quoted Price in Active Market (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) December 31, 2020: Contingent consideration liabilities- current $ 49 $ — $ — $ 49 Contingent consideration liabilities- non-current 95 — — 95 Total contingent consideration $ 144 $ — $ — $ 144 | Total Quoted Price in Active Market (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) December 31, 2019: Contingent consideration liabilities- current $ 1,864 $ — $ — $ 1,864 Contingent consideration liabilities- non-current 230 — — 230 Total contingent consideration $ 2,094 $ — $ — $ 2,094 |
Schedule of Liabilities Measured on Recurring Basis, Unobservable Inputs | A change in estimated net sales for future royalty payment periods would be expected to have a material impact on the fair value of royalty payments. Year Ended December 31, 2020 2019 (in thousands) Beginning Balance as of January 1 $ 2,094 $ 2,496 Contingent consideration liabilities settled (2,126) (139) Loss/(Gain) from change in fair value of contingent consideration recorded in general and administrative expenses 176 (263) Ending Balance as of December 31 $ 144 $ 2,094 |
STOCK-BASED COMPENSATION (Table
STOCK-BASED COMPENSATION (Tables) | 12 Months Ended |
Dec. 31, 2020 | |
Share-based Payment Arrangement [Abstract] | |
Schedule of Stock-Based Compensation Expense | Stock-based compensation expense, all related to employees and non-employee directors, was recognized as follows: December 31, 2020 2019 (In Thousands) Selling and marketing $ 2,530 1,628 General and administrative 5,607 $ 4,607 Research and development 1,831 1,278 Cost of goods sold 389 293 Total stock-based compensation expense 10,357 7,806 |
Schedule of Share-based Compensation, Restricted Stock Units Award Activity | The following table summarizes restricted stock awards and restricted stock units granted to SeaSpine employees and non-employee directors during 2020: Restricted Stock Awards and Units Shares Weighted Average Grant Date Fair Value Per Share Unvested, January 1, 2020 852 $12.21 Granted 512 12.12 Cancellations (42) 13.64 Released/Vested (525) 11.25 Unvested, December 31, 2020 797 12.71 |
Schedule of Valuation Assumptions for Stock Options | The following weighted-average assumptions were used in the calculation of fair value for options granted during the period indicated. December 31, 2020 2019 Expected dividend yield 0 % 0 % Risk-free interest rate 1.3 % 2.5 % Expected volatility 46.4 % 30.2 % Expected term (in years) 4.9 5.0 |
Schedule of Stock Option Activity | A summary of the options granted during 2020 and the total number of options outstanding as of December 31, 2020 and changes since January 1, 2020 are set forth below: Number of Shares Outstanding (In thousands) Weighted Average Exercise Price Weighted Average Remaining Contractual Life (In years) Aggregate Intrinsic Value (In thousands) Outstanding, January 1, 2020 2,637 $ 15.18 4.65 $ 506 Granted 955 $ 11.67 — — Exercised (117) $ 10.87 — — Forfeited (157) $ 14.96 — — Outstanding, December 31, 2020 3,318 $ 14.33 4.67 $ 10,667 Vested or expected to vest, December 31, 2020 3,285 $ 14.33 4.64 $ 10,537 Exercisable, December 31, 2020 2,397 $ 14.59 3.85 $ 6,993 |
Schedule of Valuation Assumptions for ESPP | The following weighted average assumptions were used in the calculation of fair value of shares under the ESPP at the grant date for the periods indicated: December 31, 2020 2019 Expected dividend yield 0 % 0 % Risk-free interest rate 0.7 % 1.4 % Expected volatility 24.6 % 21.9 % Expected term (in years) 0.7 0.7 |
LEASE (Tables)
LEASE (Tables) | 12 Months Ended |
Dec. 31, 2020 | |
Leases [Abstract] | |
Schedule of New Accounting Pronouncements and Changes in Accounting Principles | The impact of the adoption of Topic 842 to the Company's applicable balance sheet items as of January 1, 2020 is presented in the table below. The standard did not have a material impact to the Company's unaudited condensed consolidated statements of operations or comprehensive loss or cash flows. (in thousands) December 31, 2019 Impact of Adoption of ASC 842 January 1, 2020 ASSETS Right of use assets $ — $ 9,059 $ 9,059 Total assets $ 141,718 $ 9,059 $ 150,777 LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities: Other accrued expenses and current liabilities 5,444 (138) 5,306 Current portion of operating lease liabilities — 2,080 2,080 Total current liabilities 30,478 1,942 32,420 Operating lease liabilities, net of current portion — 8,367 8,367 Other liabilities 1,480 (1,250) 230 Total liabilities $ 31,958 $ 9,059 $ 41,017 Total stockholders' equity $ 109,760 $ — $ 109,760 Total liabilities and stockholders' equity $ 141,718 $ 9,059 $ 150,777 |
Schedule of Future Minimum Rental Payments for Operating Leases | A summary of the Company's remaining lease liabilities at December 31, 2020 are as follows: Payments Due by Calendar Year (In thousands) 2021 $ 2,644 2022 2,243 2023 1,568 2024 1,374 2025 1,409 Thereafter 1,869 Total undiscounted value of lease liabilities $ 11,107 Less: present value adjustment (1,737) Less: short-term leases not capitalized (421) Present value of lease liabilities 8,949 Less: current portion of lease liability (2,147) Operating lease liability, less current portion $ 6,802 |
INCOME TAXES (Tables)
INCOME TAXES (Tables) | 12 Months Ended |
Dec. 31, 2020 | |
Income Tax Disclosure [Abstract] | |
Schedule of Income before Income Tax, Domestic and Foreign | before income taxes consisted of: Year Ended December 31, 2020 2019 (In thousands) United States operations $ (42,251) $ (39,342) Foreign operations (712) 422 $ (42,963) $ (38,920) |
Schedule of effective income tax rate reconciliation | A reconciliation of the U.S. federal statutory rate to the Company’s effective tax rate is: Year Ended December 31, 2020 2019 Federal statutory rate 21.0% 21.0% Increase (decrease) in income taxes resulting from: State income taxes, net of federal tax benefit 2.0% 2.7% Foreign operations (0.3)% (0.8)% Changes in valuation allowances (22.3)% (24.7)% Uncertain tax positions —% 0.1% Research and development credit 0.6% 0.2% Other (1.5)% 0.6% Effective tax rate (0.5)% (0.9)% |
Schedule of Components of Income Tax Expense (Benefit) | The provision/(benefit) for income taxes consisted of: Year Ended December 31, 2020 2019 (In thousands) Current: Federal $ — $ (27) State 87 59 Foreign 28 39 Total current $ 115 $ 71 Deferred: Federal — — State — — Foreign 103 285 Total deferred $ 103 $ 285 Provision for income taxes $ 218 $ 356 |
Schedule of Deferred Tax Assets and Liabilities | The income tax effects of significant temporary differences that give rise to deferred tax assets and liabilities, shown before jurisdictional netting, are presented below: Year Ended December 31, 2020 2019 (In thousands) Deferred tax assets: Doubtful accounts $ 47 $ 27 Inventory related items 12,317 10,508 Tax credits 563 319 Accrued vacation 536 369 Accrued bonus 517 1,099 Stock compensation 4,947 4,431 Net operating loss carryforwards 45,744 38,149 Intangible and fixed assets 10,740 10,806 Other 704 1,000 Total deferred tax assets 76,115 66,708 Less valuation allowance (75,147) (65,576) Deferred tax assets after valuation allowance $ 968 $ 1,132 Deferred tax liabilities: Other 927 988 Total deferred tax liabilities $ 927 $ 988 Net deferred tax assets $ 41 $ 144 |
Schedule of Unrecognized Tax Benefits Roll Forward | A reconciliation of the Company’s uncertain tax benefits is as follows: Year Ended December 31, 2020 2019 (In thousands) Balance, beginning of year $ 319 $ 255 Gross increases: Prior years’ tax positions 74 15 Additions to tax positions in prior years due to spin-off — — Current year tax positions 170 75 Gross decreases: Settlements — — Statute of limitations lapses — (26) Balance, end of year $ 563 $ 319 |
SEGMENT AND GEOGRAPHIC INFORM_2
SEGMENT AND GEOGRAPHIC INFORMATION (Tables) | 12 Months Ended |
Dec. 31, 2020 | |
Segment Reporting [Abstract] | |
Schedule of Revenue by Segment | : Year Ended December 31, 2020 United States International Total (In thousands) Orthobiologics $ 71,346 $ 7,037 $ 78,383 Spinal implants $ 67,550 $ 8,412 75,962 Total revenue, net $ 138,896 $ 15,449 $ 154,345 Year Ended December 31, 2019 United States International Total (In thousands) Orthobiologics $ 73,543 $ 7,756 $ 81,299 Spinal implants $ 68,308 $ 9,476 $ 77,784 Total revenue, net $ 141,851 $ 17,232 $ 159,083 |
SELECTED QUARTERLY INFORMATIO_2
SELECTED QUARTERLY INFORMATION - UNAUDITED (Tables) | 12 Months Ended |
Dec. 31, 2020 | |
Quarterly Financial Information Disclosure [Abstract] | |
Schedule of Quarterly Financial Information | First Quarter Second Quarter Third Quarter Fourth Quarter (In thousands, except per share data) Total revenue, net: 2020 $ 36,111 $ 28,589 $ 43,209 $ 46,436 2019 36,150 39,306 39,888 43,739 Gross profit: 2020 $ 22,299 $ 16,930 $ 29,135 $ 29,140 2019 22,571 24,989 25,481 28,063 Net loss: 2020 $ (12,551) $ (13,713) $ (6,574) $ (10,343) 2019 (8,989) (12,036) (9,663) (8,588) Basic/diluted net loss per common share (1) : 2020 $ (0.48) $ (0.50) $ (0.24) $ (0.37) 2019 (0.48) (0.64) (0.51) (0.45) (1) Per common share amounts for the quarters and full years have been calculated separately. Accordingly, quarterly amounts do not necessarily add to the annual amount because of differences in the weighted average common shares outstanding during each period principally due to the effect of the Company’s issuing or canceled shares of its common stock during the year. |
BUSINESS Narrative (Details)
BUSINESS Narrative (Details) | 12 Months Ended |
Dec. 31, 2020 | |
Supplier Concentration Risk [Member] | |
Concentration Risk [Line Items] | |
Concentration Risk, Percentage | 10.00% |
SUMMARY OF SIGNIFICANT ACCOUN_3
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Narrative (Details) - USD ($) $ in Thousands, shares in Millions | 12 Months Ended | ||
Dec. 31, 2020 | Dec. 31, 2019 | Jan. 01, 2020 | |
New Accounting Pronouncements or Change in Accounting Principle [Line Items] | |||
Operating Lease, Right-of-Use Asset | $ 7,658 | $ 0 | $ 9,059 |
Operating Lease, Liability | $ 8,949 | ||
Product royalties as a percent of total revenue, less than (as a percent) | 1.00% | 1.00% | |
Product royalties as a percent of total revenue, less than (as a percent) | 1.00% | 1.00% | |
Other Cost and Expense, Operating | $ 2,500 | $ 2,500 | |
Stock-based compensation expense | $ 10,357 | $ 7,806 | |
Antidilutive dilutive securities (in shares) | 4.2 | 3.6 | |
Accounting Standards Update 2016-02 [Member] | |||
New Accounting Pronouncements or Change in Accounting Principle [Line Items] | |||
Operating Lease, Right-of-Use Asset | 9,059 | ||
Operating Lease, Liability | 10,500 | ||
Accrued Rent | $ 1,400 |
DEBT AND INTEREST Credit Agreem
DEBT AND INTEREST Credit Agreement (Details) | Dec. 24, 2015USD ($)extension | Dec. 31, 2020USD ($) | Dec. 31, 2019USD ($) |
Line of Credit Facility [Line Items] | |||
Remaining borrowing capacity | $ 23,000,000 | ||
Credit Agreement | |||
Line of Credit Facility [Line Items] | |||
Line of Credit Facility, Expiration Period | 3 years | ||
Number of extensions | extension | 1 | ||
Line Of Credit Facility, Extension Period | 1 year | ||
Debt Issuance Costs, Line of Credit Arrangements, Gross | $ 0.6 | ||
Minimum fixed charge ratio | 1.10 | ||
Minimum liquidity | $ 5,000,000 | ||
Credit Agreement | Minimum | |||
Line of Credit Facility [Line Items] | |||
Average excess availability | $ 10,000,000 | ||
Unused line fee (as a percent) | 0.375% | ||
Credit Agreement | Maximum | |||
Line of Credit Facility [Line Items] | |||
Average excess availability | $ 20,000,000 | ||
Unused line fee (as a percent) | 0.50% | ||
Credit Agreement | Revolving Credit Facility | |||
Line of Credit Facility [Line Items] | |||
Borrowing capacity | $ 30,000,000 | ||
Line of Credit Facility, Increase in Borrowing Capacity | $ 10,000,000 | ||
Long-term Line of Credit | $ 0 | $ 0 | |
Credit Agreement, Contingent Interest Rate One | Base Rate | |||
Line of Credit Facility [Line Items] | |||
Interest rate (as a percent) | 1.25% | ||
Credit Agreement, Contingent Interest Rate One | LIBOR | |||
Line of Credit Facility [Line Items] | |||
Interest rate (as a percent) | 2.25% | ||
Credit Agreement. Contingent Interest Rate Two | Base Rate | |||
Line of Credit Facility [Line Items] | |||
Interest rate (as a percent) | 1.50% | ||
Credit Agreement. Contingent Interest Rate Two | LIBOR | |||
Line of Credit Facility [Line Items] | |||
Interest rate (as a percent) | 2.50% | ||
Credit Agreement, Contingent Interest Rate Three | Base Rate | |||
Line of Credit Facility [Line Items] | |||
Interest rate (as a percent) | 1.75% | ||
Credit Agreement, Contingent Interest Rate Three | LIBOR | |||
Line of Credit Facility [Line Items] | |||
Interest rate (as a percent) | 2.75% |
Paycheck Protection Program (De
Paycheck Protection Program (Details) $ in Thousands | 12 Months Ended |
Dec. 31, 2020USD ($) | |
Debt Disclosure [Abstract] | |
Notes Payable | $ 7,200 |
Repayments of Notes Payable | $ 1,000 |
BALANCE SHEET DETAILS Schedule
BALANCE SHEET DETAILS Schedule of Inventories, Net (Details) - USD ($) $ in Thousands | Dec. 31, 2020 | Dec. 31, 2019 |
Balance Sheet Related Disclosures [Abstract] | ||
Finished goods | $ 37,689 | $ 30,042 |
Work in process | 10,087 | 10,847 |
Raw materials | 6,265 | 6,266 |
Inventories, net | $ 54,041 | $ 47,155 |
BALANCE SHEET DETAILS Property,
BALANCE SHEET DETAILS Property, Plant and Equipment Balances (Details) - USD ($) $ in Thousands | 12 Months Ended | |
Dec. 31, 2020 | Dec. 31, 2019 | |
Property, Plant and Equipment [Line Items] | ||
Total | $ 67,667 | $ 58,521 |
Less accumulated depreciation and amortization | (36,245) | (32,770) |
Property, plant and equipment, net | 31,422 | 25,751 |
Leasehold improvements | ||
Property, Plant and Equipment [Line Items] | ||
Total | $ 5,976 | 5,878 |
Leasehold improvements | Minimum | ||
Property, Plant and Equipment [Line Items] | ||
Useful Lives (in years) | 1 year | |
Leasehold improvements | Maximum | ||
Property, Plant and Equipment [Line Items] | ||
Useful Lives (in years) | 20 years | |
Machinery and production equipment | ||
Property, Plant and Equipment [Line Items] | ||
Total | $ 9,577 | 8,562 |
Machinery and production equipment | Minimum | ||
Property, Plant and Equipment [Line Items] | ||
Useful Lives (in years) | 3 years | |
Machinery and production equipment | Maximum | ||
Property, Plant and Equipment [Line Items] | ||
Useful Lives (in years) | 10 years | |
Spinal instruments and sets | ||
Property, Plant and Equipment [Line Items] | ||
Total | $ 30,275 | 25,511 |
Spinal instruments and sets | Minimum | ||
Property, Plant and Equipment [Line Items] | ||
Useful Lives (in years) | 4 years | |
Spinal instruments and sets | Maximum | ||
Property, Plant and Equipment [Line Items] | ||
Useful Lives (in years) | 5 years | |
Information systems and hardware | ||
Property, Plant and Equipment [Line Items] | ||
Total | $ 7,554 | 7,442 |
Information systems and hardware | Minimum | ||
Property, Plant and Equipment [Line Items] | ||
Useful Lives (in years) | 3 years | |
Information systems and hardware | Maximum | ||
Property, Plant and Equipment [Line Items] | ||
Useful Lives (in years) | 7 years | |
Furniture and fixtures | ||
Property, Plant and Equipment [Line Items] | ||
Total | $ 1,640 | 1,412 |
Furniture and fixtures | Minimum | ||
Property, Plant and Equipment [Line Items] | ||
Useful Lives (in years) | 3 years | |
Furniture and fixtures | Maximum | ||
Property, Plant and Equipment [Line Items] | ||
Useful Lives (in years) | 5 years | |
Construction in progress | ||
Property, Plant and Equipment [Line Items] | ||
Total | $ 12,645 | $ 9,716 |
BALANCE SHEET DETAILS Propert_2
BALANCE SHEET DETAILS Property, Plant and Equipment Narrative (Details) - USD ($) $ in Thousands | 12 Months Ended | |
Dec. 31, 2020 | Dec. 31, 2019 | |
Property, Plant and Equipment [Line Items] | ||
Depreciation | $ 6,500 | $ 4,900 |
Instrument replacement expense | 2,799 | 2,281 |
Cost of goods sold | ||
Property, Plant and Equipment [Line Items] | ||
Depreciation | $ 1,000 | $ 900 |
BALANCE SHEET DETAILS Identifia
BALANCE SHEET DETAILS Identifiable Intangible Assets Acquired (Details) - USD ($) $ in Thousands | 12 Months Ended | |
Dec. 31, 2020 | Dec. 31, 2019 | |
Product technology | ||
Finite-Lived Intangible Assets [Line Items] | ||
Finite-lived Intangible Assets Acquired | $ 300 | $ 900 |
BALANCE SHEET DETAILS Component
BALANCE SHEET DETAILS Components of Company's Identifiable Intangible Assets (Details) - USD ($) $ in Thousands | 12 Months Ended | |
Dec. 31, 2020 | Dec. 31, 2019 | |
Finite-Lived Intangible Assets [Line Items] | ||
Cost | $ 90,021 | $ 91,288 |
Accumulated Amortization | (76,138) | (72,115) |
Net | $ 13,883 | $ 19,173 |
Product technology | ||
Finite-Lived Intangible Assets [Line Items] | ||
Weighted Average Life (in years) | 12 years | 12 years |
Cost | $ 32,891 | $ 34,158 |
Accumulated Amortization | (29,766) | (28,912) |
Net | $ 3,125 | $ 5,246 |
Customer relationships | ||
Finite-Lived Intangible Assets [Line Items] | ||
Weighted Average Life (in years) | 12 years | 12 years |
Cost | $ 56,830 | $ 56,830 |
Accumulated Amortization | (46,072) | (42,903) |
Net | 10,758 | 13,927 |
Trademarks/brand names | ||
Finite-Lived Intangible Assets [Line Items] | ||
Cost | 300 | 300 |
Accumulated Amortization | (300) | (300) |
Net | $ 0 | $ 0 |
BALANCE SHEET DETAILS Identif_2
BALANCE SHEET DETAILS Identifiable Intangible Assets Narrative (Details) - USD ($) $ in Millions | 12 Months Ended | |
Dec. 31, 2020 | Dec. 31, 2019 | |
Finite-Lived Intangible Assets [Line Items] | ||
Annual amortization expense expected to approximate in 2021 | $ 4.2 | |
Annual amortization expense expected to approximate in 2022 | 4.1 | |
Annual amortization expense expected to approximate in 2023 | 3.4 | |
Annual amortization expense expected to approximate in 2024 | 1.5 | |
Annual amortization expense expected to approximate in 2025 | 0.2 | |
Intangible asset amortization | 4.2 | $ 5.4 |
Product technology | Cost of goods sold | ||
Finite-Lived Intangible Assets [Line Items] | ||
Intangible asset amortization | $ 1 | $ 2.2 |
FAIR VALUE MEASUREMENTS - Fair
FAIR VALUE MEASUREMENTS - Fair Value on Recurring Basis (Details) - USD ($) $ in Thousands | 12 Months Ended | |||
Dec. 31, 2020 | Dec. 31, 2019 | Dec. 31, 2018 | Sep. 26, 2016 | |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||||
Stock Issued During Period, Value, Acquisitions | $ 2,000 | |||
Recurring | ||||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||||
Contingent consideration liabilities- current | 49 | $ 1,864 | ||
Contingent consideration liabilities- non-current | 95 | 230 | ||
Total contingent consideration | 144 | 2,094 | ||
Recurring | Level 1 | ||||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||||
Contingent consideration liabilities- current | 0 | 0 | ||
Contingent consideration liabilities- non-current | 0 | 0 | ||
Total contingent consideration | 0 | 0 | ||
Recurring | Level 2 | ||||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||||
Contingent consideration liabilities- current | 0 | 0 | ||
Contingent consideration liabilities- non-current | 0 | 0 | ||
Total contingent consideration | 0 | 0 | ||
Recurring | Level 3 | ||||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||||
Contingent consideration liabilities- current | 49 | 1,864 | ||
Contingent consideration liabilities- non-current | 95 | 230 | ||
Total contingent consideration | $ 144 | $ 2,094 | $ 2,496 | |
Milestone Payment [Member] | ||||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||||
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High | $ 5,000 | |||
Royalty payment [Member] | ||||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||||
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High | 43,000 | |||
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, Low | $ 18,000 |
FAIR VALUE MEASUREMENTS - Chang
FAIR VALUE MEASUREMENTS - Changes in Contingent Consideration Liabilities (Details) - Recurring - USD ($) $ in Thousands | 12 Months Ended | ||
Dec. 31, 2020 | Dec. 31, 2019 | Dec. 31, 2018 | |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | |||
Contingent Consideration Liability, Fair Value Disclosure | $ 144 | $ 2,094 | |
Level 1 | |||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | |||
Contingent Consideration Liability, Fair Value Disclosure | 0 | 0 | |
Level 2 | |||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | |||
Contingent Consideration Liability, Fair Value Disclosure | 0 | 0 | |
Level 3 | |||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | |||
Contingent Consideration Liability, Fair Value Disclosure | 144 | 2,094 | $ 2,496 |
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements | (2,126) | (139) | |
Selling, General and Administrative Expenses [Member] | Level 3 | |||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | |||
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings | $ 176 | $ (263) |
STOCK-BASED COMPENSATION Common
STOCK-BASED COMPENSATION Common Stock (Details) - USD ($) $ / shares in Units, $ in Thousands | Aug. 17, 2020 | Jul. 28, 2020 | Jan. 10, 2020 | Dec. 31, 2020 | Dec. 31, 2019 |
Share-based Payment Arrangement [Abstract] | |||||
Stock Issued During Period, Shares, Acquisitions | 75,585 | 100,100 | |||
Shares Issued, Price Per Share | $ 12.50 | ||||
Stock Issued During Period, Shares, New Issues | 7,820,000 | ||||
Proceeds from issuance of common stock, net of offering costs | $ 91,600 | $ 91,622 | $ 0 |
STOCK-BASED COMPENSATION Stock-
STOCK-BASED COMPENSATION Stock-Based Compensation Expense Breakout (Details) - USD ($) $ in Thousands | 12 Months Ended | |
Dec. 31, 2020 | Dec. 31, 2019 | |
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items] | ||
Total stock-based compensation expense | $ 10,357 | $ 7,806 |
Share-based Payment Arrangement, Expense, Tax Benefit | 0 | 0 |
Selling and Marketing Expense [Member] | ||
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items] | ||
Total stock-based compensation expense | 2,530 | 1,628 |
General and Administrative Expense [Member] | ||
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items] | ||
Total stock-based compensation expense | 5,607 | 4,607 |
Research and development | ||
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items] | ||
Total stock-based compensation expense | 1,831 | 1,278 |
Cost of goods sold | ||
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items] | ||
Total stock-based compensation expense | $ 389 | $ 293 |
STOCK-BASED COMPENSATION Equity
STOCK-BASED COMPENSATION Equity Award Plans (Details) - shares | Apr. 13, 2020 | Mar. 22, 2018 | Dec. 31, 2020 |
2015 Plan | |||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||
Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized | 3,500,000 | 2,726,000 | |
Number of shares authorized (in share) | 9,735,500 | ||
Number of shares available for grant (in shares) | 4,011,104 | ||
2018 Plan [Member] | |||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||
Number of shares authorized (in share) | 2,000,000 | ||
Number of shares available for grant (in shares) | 1,914,793 | ||
2020 Plan [Member] | |||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||
Number of shares authorized (in share) | 2,000,000 | ||
Number of shares available for grant (in shares) | 1,928,257 |
STOCK-BASED COMPENSATION Restri
STOCK-BASED COMPENSATION Restricted Stock Awards and Restricted Stock Units Narrative (Details) - USD ($) $ / shares in Units, $ in Thousands | 12 Months Ended | |
Dec. 31, 2020 | Dec. 31, 2019 | |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||
Stock-based compensation | $ 10,357 | $ 7,806 |
Restricted Stock and Restricted Stock Unit | ||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value | $ 12.12 | $ 16.31 |
Fair market value of shares vested | $ 6,000 | $ 4,300 |
Stock-based compensation | 5,700 | $ 5,900 |
Unrecognized compensation expense | $ 2,900 | |
Recognition period (in years) | 1 year 2 months 12 days | |
Restricted Stock and Restricted Stock Unit | Employee | ||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||
Forfeiture rate (as a percent) | 13.00% | 14.00% |
Restricted Stock and Restricted Stock Unit | Director | ||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||
Forfeiture rate (as a percent) | 0.00% | 0.00% |
Restricted Stock and Restricted Stock Unit | Executive Officer | ||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||
Forfeiture rate (as a percent) | 0.00% | 0.00% |
STOCK-BASED COMPENSATION Rest_2
STOCK-BASED COMPENSATION Restricted Stock Awards and Restricted Stock Units Activity (Details) - Restricted Stock and Restricted Stock Unit - $ / shares shares in Thousands | 12 Months Ended | |
Dec. 31, 2020 | Dec. 31, 2019 | |
Shares (In thousands) | ||
Unvested at beginning of period (in shares) | 852 | |
Granted (in shares) | 512 | |
Cancellations (in shares) | (42) | |
Released/Vested (in shares) | (525) | |
Unvested at end of period (in shares) | 797 | 852 |
Weighted Average Grant Date Fair Value Per Share | ||
Unvested at beginning of period (in dollars per share) | $ 12.21 | |
Granted (in dollars per share) | 12.12 | $ 16.31 |
Cancellations (in dollars per share) | 13.64 | |
Released/Vested (in dollars per share) | 11.25 | |
Unvested at end of period (in dollars per share) | $ 12.71 | $ 12.21 |
STOCK-BASED COMPENSATION Stock
STOCK-BASED COMPENSATION Stock Options Narrative (Details) - USD ($) $ / shares in Units, $ in Thousands | 12 Months Ended | |
Dec. 31, 2020 | Dec. 31, 2019 | |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||
Stock-based compensation | $ 10,357 | $ 7,806 |
Share-based Payment Arrangement, Expense, Tax Benefit | $ 0 | $ 0 |
Employee Stock Option | ||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value | $ 4.79 | $ 4.14 |
Fair value of options vested | $ 2,100 | $ 1,300 |
Stock-based compensation | 3,800 | $ 1,200 |
Unrecognized compensation cost | $ 1,800 | |
Recognition period (in years) | 1 year 6 months | |
Employee | ||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||
Requisite service period (in years) | 4 years | |
Employee | Employee Stock Option | ||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||
Forfeiture rate (as a percent) | 13.00% | 14.00% |
Director | ||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||
Requisite service period (in years) | 1 year | |
Director | Employee Stock Option | ||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||
Forfeiture rate (as a percent) | 0.00% | 0.00% |
Executive Officer | Employee Stock Option | ||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||
Forfeiture rate (as a percent) | 0.00% | 0.00% |
STOCK-BASED COMPENSATION Stoc_2
STOCK-BASED COMPENSATION Stock Options Weighted-Average Assumptions (Details) - Employee Stock Option - $ / shares | 12 Months Ended | |
Dec. 31, 2020 | Dec. 31, 2019 | |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value | $ 4.79 | $ 4.14 |
Expected dividend yield (as a percent) | 0.00% | 0.00% |
Risk-free interest rate (as a percent) | 1.30% | 2.50% |
Expected volatility (as a percent) | 46.40% | 30.20% |
Expected term (in years) | 4 years 10 months 24 days | 5 years |
STOCK-BASED COMPENSATION Stoc_3
STOCK-BASED COMPENSATION Stock Options Activity (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands | 12 Months Ended | |
Dec. 31, 2020 | Dec. 31, 2019 | |
Additional Information | ||
Stock-based compensation | $ 10,357 | $ 7,806 |
Employee Stock Option | ||
Number of Shares Outstanding (In thousands) | ||
Outstanding at beginning of period (in shares) | 2,637 | |
Granted (in shares) | 955 | |
Exercised (in shares) | (117) | |
Forfeited (in shares) | (157) | |
Outstanding at end of period (in shares) | 3,318 | 2,637 |
Weighted Average Exercise Price | ||
Outstanding at beginning of period (in dollars per share) | $ 15.18 | |
Granted (in dollars per share) | 11.67 | |
Exercised (in dollars per share) | 10.87 | |
Forfeited (in dollars per share) | 14.96 | |
Outstanding at end of period (in dollars per share) | $ 14.33 | $ 15.18 |
Vested or expected to vest | ||
Number of Shares Outstanding (In thousands) (in shares) | 3,285 | |
Weighted Average Exercise Price (in dollars per share) | $ 14.33 | |
Weighted Average Remaining Contractual Life (In years) | 4 years 7 months 20 days | |
Aggregate Intrinsic Value (In thousands) | $ 10,537 | |
Additional Information | ||
Outstanding, Weighted Average Remaining Contractual Life (In years) | 4 years 8 months 1 day | 4 years 7 months 24 days |
Outstanding, Aggregate Intrinsic Value (In thousands) | $ 10,667 | $ 506 |
Exercisable, Number of Shares Outstanding (In thousands) (in shares) | 2,397 | |
Exercisable, Weighted Average Exercise Price (in dollars per share) | $ 14.59 | |
Exercisable, Weighted Average Remaining Contractual Life (In years) | 3 years 10 months 6 days | |
Exercisable, Aggregate Intrinsic Value (In thousands) | $ 6,993 | |
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value | $ 4.79 | $ 4.14 |
Fair value of options vested | $ 2,100 | $ 1,300 |
Stock-based compensation | $ 3,800 | $ 1,200 |
STOCK-BASED COMPENSATION Employ
STOCK-BASED COMPENSATION Employee Stock Purchase Plan Narrative (Details) - USD ($) | Dec. 08, 2020 | Dec. 31, 2020 | Dec. 31, 2019 | Dec. 31, 2018 | Nov. 02, 2018 |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||||
Compensation expense | $ 10,357,000 | $ 7,806,000 | |||
Employee Stock Purchase Plan | |||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||||
Compensation expense | $ 900,000 | $ 700,000 | |||
Employee Stock Purchase Plan | Employee Stock | |||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||||
Maximum contributions (as a percent) | 15.00% | ||||
Maximum shares investment allowed | 2,500 | ||||
Maximum annual contributions | $ 25,000 | ||||
Purchase price (as a percent) | 85.00% | ||||
Number of shares authorized (in share) | 800,000 | ||||
Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized | 500,000 | 400,000 | |||
Number of shares purchased | 153,302 | 119,602 | |||
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant | 127,160 |
STOCK-BASED COMPENSATION Empl_2
STOCK-BASED COMPENSATION Employee Stock Purchase Plan Weighted-Average Assumptions (Details) - Employee Stock Purchase Plan | 12 Months Ended | |
Dec. 31, 2020 | Dec. 31, 2019 | |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||
Expected dividend yield (as a percent) | 0.00% | 0.00% |
Risk-free interest rate (as a percent) | 0.70% | 1.40% |
Expected volatility (as a percent) | 24.60% | 21.90% |
Expected term (in years) | 8 months 12 days | 8 months 12 days |
LEASES Impact of Adoption Topic
LEASES Impact of Adoption Topic 842 (Details) - USD ($) $ in Thousands | Dec. 31, 2020 | Jan. 01, 2020 | Dec. 31, 2019 | Dec. 31, 2018 |
New Accounting Pronouncements or Change in Accounting Principle [Line Items] | ||||
Operating Lease, Right-of-Use Asset | $ 7,658 | $ 9,059 | $ 0 | |
Assets | 214,401 | 150,777 | 141,718 | |
Other accrued expenses and current liabilities | 6,014 | 5,306 | 5,444 | |
Operating Lease, Liability, Current | 2,147 | 2,080 | 0 | |
Liabilities, Current | 30,727 | 32,420 | 30,478 | |
Operating Lease, Liability, Noncurrent | 6,802 | 8,367 | 0 | |
Other liabilities | 95 | 230 | 1,480 | |
Liabilities | 42,683 | 41,017 | 31,958 | |
Stockholders' Equity Attributable to Parent | 171,718 | 109,760 | 109,760 | $ 142,085 |
Liabilities and Equity | $ 214,401 | 150,777 | $ 141,718 | |
Accounting Standards Update 2016-02 [Member] | ||||
New Accounting Pronouncements or Change in Accounting Principle [Line Items] | ||||
Operating Lease, Right-of-Use Asset | 9,059 | |||
Assets | 9,059 | |||
Other accrued expenses and current liabilities | (138) | |||
Operating Lease, Liability, Current | 2,080 | |||
Liabilities, Current | 1,942 | |||
Operating Lease, Liability, Noncurrent | 8,367 | |||
Other liabilities | (1,250) | |||
Liabilities | 9,059 | |||
Stockholders' Equity Attributable to Parent | 0 | |||
Liabilities and Equity | $ 9,059 |
LEASES Lease Cost (Details)
LEASES Lease Cost (Details) - USD ($) $ in Thousands | 12 Months Ended | |
Dec. 31, 2020 | Dec. 31, 2019 | |
Leases [Abstract] | ||
Operating Lease, Weighted Average Remaining Lease Term | 5 years 3 months 18 days | |
Operating Lease, Weighted Average Discount Rate, Percent | 6.50% | |
Operating Lease, Expense | $ 2,100 | $ 2,100 |
LEASE Future Lease Payments (De
LEASE Future Lease Payments (Details) - USD ($) $ in Thousands | Dec. 31, 2020 | Jan. 01, 2020 | Dec. 31, 2019 |
Leases [Abstract] | |||
2021 | $ 2,644 | ||
2022 | 2,243 | ||
2023 | 1,568 | ||
2024 | 1,374 | ||
2025 | 1,409 | ||
Thereafter | 1,869 | ||
Total undiscounted value of lease liabilities | 11,107 | ||
Lessee, Operating Lease, Liability, Undiscounted Excess Amount | (1,737) | ||
Operating Lease, Liability, Not Capitalized | (421) | ||
Operating Lease, Liability | 8,949 | ||
Operating Lease, Liability, Current | (2,147) | $ (2,080) | $ 0 |
Operating Lease, Liability, Noncurrent | $ 6,802 | $ 8,367 | $ 0 |
INCOME TAXES Loss before income
INCOME TAXES Loss before income taxes (Details) - USD ($) $ in Thousands | 12 Months Ended | |
Dec. 31, 2020 | Dec. 31, 2019 | |
Income Tax Disclosure [Abstract] | ||
United States operations | $ (42,251) | $ (39,342) |
Foreign operations | (712) | 422 |
Loss before income taxes | $ (42,963) | $ (38,920) |
INCOME TAXES Reconciliation of
INCOME TAXES Reconciliation of the U.S. federal statutory rate to the Company’s effective tax rate (Details) | 12 Months Ended | |
Dec. 31, 2020 | Dec. 31, 2019 | |
Income Tax Disclosure [Abstract] | ||
Federal statutory rate | 21.00% | 21.00% |
Increase (decrease) in income taxes resulting from: | ||
State income taxes, net of federal tax benefit | 2.00% | 2.70% |
Foreign operations | (0.30%) | (0.80%) |
Changes in valuation allowances | (22.30%) | (24.70%) |
Uncertain tax positions | 0.00% | 0.10% |
Research and development credit | 0.60% | 0.20% |
Other | (1.50%) | 0.60% |
Effective tax rate | (0.50%) | (0.90%) |
INCOME TAXES Provision for inco
INCOME TAXES Provision for income taxes (Details) - USD ($) $ in Thousands | 12 Months Ended | |
Dec. 31, 2020 | Dec. 31, 2019 | |
Current: | ||
Federal | $ 0 | $ (27) |
State | 87 | 59 |
Foreign | 28 | 39 |
Total current | 115 | 71 |
Deferred: | ||
Federal | 0 | 0 |
State | 0 | 0 |
Foreign | 103 | 285 |
Total deferred | 103 | 285 |
Provision for income taxes | $ 218 | $ 356 |
INCOME TAXES Deferred tax asset
INCOME TAXES Deferred tax assets and liabilities (Details) - USD ($) $ in Thousands | Dec. 31, 2020 | Dec. 31, 2019 |
Deferred tax assets: | ||
Doubtful accounts | $ 47 | $ 27 |
Inventory related items | 12,317 | 10,508 |
Tax credits | 563 | 319 |
Accrued vacation | 536 | 369 |
Accrued bonus | 517 | 1,099 |
Stock compensation | 4,947 | 4,431 |
Net operating loss carryforwards | 45,744 | 38,149 |
Intangible & fixed assets | 10,740 | 10,806 |
Other | 704 | 1,000 |
Deferred tax liabilities: | ||
Deferred Tax Assets, Gross, Total | 76,115 | 66,708 |
Deferred Tax Assets, Valuation Allowance | 75,147 | 65,576 |
Deferred Tax Assets, Net of Valuation Allowance, Total | 968 | 1,132 |
Deferred Tax Liabilities, Other | 927 | 988 |
Deferred Tax Liabilities, Net, Total | 927 | 988 |
Deferred Tax Assets, Net | $ 41 | $ 144 |
INCOME TAXES Narrative (Details
INCOME TAXES Narrative (Details) - USD ($) $ in Millions | Dec. 31, 2020 | Dec. 31, 2019 |
Operating Loss Carryforwards [Line Items] | ||
Tax benefit | $ 0.1 | $ 0.3 |
Internal Revenue Service (IRS) And State and Local Jurisdiction | ||
Operating Loss Carryforwards [Line Items] | ||
Operating loss carryforwards | 187.7 | 156.3 |
Foreign Tax Authority | ||
Operating Loss Carryforwards [Line Items] | ||
Operating loss carryforwards | $ 0.2 | $ 0.6 |
INCOME TAXES Uncertain tax bene
INCOME TAXES Uncertain tax benefits (Details) - USD ($) $ in Thousands | 12 Months Ended | |
Dec. 31, 2020 | Dec. 31, 2019 | |
Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward] | ||
Balance, beginning of year | $ 319 | $ 255 |
Prior years’ tax positions | 74 | 15 |
Additions to tax positions in prior years due to spin-off | 0 | 0 |
Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions | 170 | 75 |
Settlements | 0 | 0 |
Statute of limitations lapses | 0 | (26) |
Balance, end of year | $ 563 | $ 319 |
SEGMENT AND GEOGRAPHIC INFORM_3
SEGMENT AND GEOGRAPHIC INFORMATION Narrative (Details) | 12 Months Ended |
Dec. 31, 2020product | |
Segment Reporting [Abstract] | |
Number of product categories | 2 |
SEGMENT AND GEOGRAPHIC INFORM_4
SEGMENT AND GEOGRAPHIC INFORMATION Revenue (Details) - USD ($) $ in Thousands | 3 Months Ended | 12 Months Ended | ||||||||
Dec. 31, 2020 | Sep. 30, 2020 | Jun. 30, 2020 | Mar. 31, 2020 | Dec. 31, 2019 | Sep. 30, 2019 | Jun. 30, 2019 | Mar. 31, 2019 | Dec. 31, 2020 | Dec. 31, 2019 | |
Segment Reporting Information [Line Items] | ||||||||||
Revenues | $ 46,436 | $ 43,209 | $ 28,589 | $ 36,111 | $ 43,739 | $ 39,888 | $ 39,306 | $ 36,150 | $ 154,345 | $ 159,083 |
United States | ||||||||||
Segment Reporting Information [Line Items] | ||||||||||
Revenues | 138,896 | 141,851 | ||||||||
International | ||||||||||
Segment Reporting Information [Line Items] | ||||||||||
Revenues | 15,449 | 17,232 | ||||||||
Orthobiologics | ||||||||||
Segment Reporting Information [Line Items] | ||||||||||
Revenues | 78,383 | 81,299 | ||||||||
Orthobiologics | United States | ||||||||||
Segment Reporting Information [Line Items] | ||||||||||
Revenues | 71,346 | 73,543 | ||||||||
Orthobiologics | International | ||||||||||
Segment Reporting Information [Line Items] | ||||||||||
Revenues | 7,037 | 7,756 | ||||||||
Spinal implants | ||||||||||
Segment Reporting Information [Line Items] | ||||||||||
Revenues | 75,962 | 77,784 | ||||||||
Spinal implants | United States | ||||||||||
Segment Reporting Information [Line Items] | ||||||||||
Revenues | 67,550 | 68,308 | ||||||||
Spinal implants | International | ||||||||||
Segment Reporting Information [Line Items] | ||||||||||
Revenues | $ 8,412 | $ 9,476 |
EMPLOYEE BENEFIT PLAN Narrative
EMPLOYEE BENEFIT PLAN Narrative (Details) - USD ($) $ in Millions | 12 Months Ended | |
Dec. 31, 2020 | Dec. 31, 2019 | |
Retirement Benefits [Abstract] | ||
Contributions | $ 1.1 | $ 0.6 |
SELECTED QUARTERLY INFORMATIO_3
SELECTED QUARTERLY INFORMATION - UNAUDITED Financials (Details) - USD ($) $ / shares in Units, $ in Thousands | 3 Months Ended | 12 Months Ended | ||||||||
Dec. 31, 2020 | Sep. 30, 2020 | Jun. 30, 2020 | Mar. 31, 2020 | Dec. 31, 2019 | Sep. 30, 2019 | Jun. 30, 2019 | Mar. 31, 2019 | Dec. 31, 2020 | Dec. 31, 2019 | |
Quarterly Financial Information Disclosure [Abstract] | ||||||||||
Revenues | $ 46,436 | $ 43,209 | $ 28,589 | $ 36,111 | $ 43,739 | $ 39,888 | $ 39,306 | $ 36,150 | $ 154,345 | $ 159,083 |
Gross profit | 29,140 | 29,135 | 16,930 | 22,299 | 28,063 | 25,481 | 24,989 | 22,571 | 97,504 | 101,104 |
Net loss | $ (10,343) | $ (6,574) | $ (13,713) | $ (12,551) | $ (8,588) | $ (9,663) | $ (12,036) | $ (8,989) | $ (43,181) | $ (39,276) |
Net Loss per share, basic and diluted (in dollars per share) | $ (0.37) | $ (0.24) | $ (0.50) | $ (0.48) | $ (0.45) | $ (0.51) | $ (0.64) | $ (0.48) | $ (1.59) | $ (2.07) |
SCHEDULE II - VALUATION AND Q_2
SCHEDULE II - VALUATION AND QUALIFYING ACCOUNTS (Details) - USD ($) $ in Thousands | 12 Months Ended | |
Dec. 31, 2020 | Dec. 31, 2019 | |
Allowance for doubtful accounts and sales returns and other credits | ||
SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward] | ||
Balance at Beginning of Period | $ 111 | $ 850 |
Charged to Costs and Expenses | 0 | 20 |
Charged to Other Accounts | 0 | (417) |
Additions/Deductions | 81 | (342) |
Balance at End of Period | 192 | 111 |
SEC Schedule, 12-09, Reserve, Inventory [Member] | ||
SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward] | ||
Balance at Beginning of Period | 32,237 | 29,309 |
Charged to Costs and Expenses | 6,903 | 4,747 |
Charged to Other Accounts | 0 | 0 |
Additions/Deductions | (1,125) | (1,819) |
Balance at End of Period | 38,015 | 32,237 |
Deferred tax asset valuation allowance | ||
SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward] | ||
Balance at Beginning of Period | 65,576 | 55,954 |
Charged to Costs and Expenses | 9,571 | 9,622 |
Charged to Other Accounts | 0 | 0 |
Additions/Deductions | 0 | 0 |
Balance at End of Period | $ 75,147 | $ 65,576 |